NORMAL PHYSIOLOGY OF ACTH AND GH RELEASE IN THE HYPOTHALAMUS AND ANTERIOR PITUITARY IN MAN

DR CHUNG THONG LIM, Cambridge University, Cambridge, UK

DR BERNARD KHOO, Division of Medicine, University College London, UK Revised 10 24 2017

ABSTRACT

Adrenocorticotropic hormone (ACTH) and growth hormone (GH) are both tropic peptide hormones secreted from the anterior pituitary. ACTH is derived from cleavage of the precursor hormone proopiomelanocortin (POMC) by prohormone convertase enzymes. The role of ACTH in the hypothalamo-pituitary axis includes stimulating the release of cortisol from the adrenal glands (the HPA system). ACTH secretion is in pulses and under negative feedback control, as well as demonstrating a circadian rhythm pattern. It is under the influence of various hormones and factors secreted in the body. Physiological activities such as eating and stress response can also affect the release of ACTH. The HPA system is known to vary with ageing and gender differences.

GH is secreted mainly by somatotrophs in the anterior pituitary but it is also expressed in other parts of the brain. Similarly to ACTH, the release of GH is pulsatile with diurnal variation, under a negative feedback autoregulation loop and can be affected by various factors. Activities that affect secretion of GH include sleep, exercise, and physical stresses such as fasting and hypoglycaemia, hyperglycaemia, hypovolaemic shock and elective surgeries. GH secretion demonstrates differences between sexes, with male 'pulsatile' secretion versus female 'continuous' secretion. In addition, the level of secretion also declines with age, a phenomenon termed 'somatopause'.

This chapter summarizes the intimate relationship between the hypothalamus and the anterior pituitary with respect to the secretion of ACTH and GH from the physiological viewpoint. Other chapters in <u>endotext.com</u> cover the hormones prolactin, LH, FSH, TSH and the posterior pituitary.

LINKS

- The functional anatomy of the hypothalamus and anterior pituitary is summarized in <u>Lechan</u> and <u>Toni</u>.
- ♦ The anatomy and physiology of the posterior pituitary is covered by <u>Ball</u>.
- ♦ Prolactin and excess prolactin secretion is discussed by <u>Glezer and Bronstein</u>.
- ♦ The physiology of the gonadotrophins is covered by <u>Marques et al</u>.
- ♦ The physiology of TSH is discussed by <u>Mariotti and Beck-Peccoz</u>.
- ♦ The physiology of GH in childhood is discussed by <u>Rozario et al.</u>
- Further information on GH physiology is available from Gunawardane et al.

THE HYPOTHALAMIC/PITUITARY INTERFACE

The hypothalamus and pituitary serves as the body's primary interface between the nervous system and the endocrine system. This interface takes the form of:

- **Amplification** from femto (10⁻¹⁵) and pico (10⁻¹²)-molar concentrations of hypophysiotropic hormones to nano (10⁻⁹) molar concentrations of pituitary hormones;
- **Temporal smoothing** from ultradian pulsed secretion of hypophysiotropic hormones to circadian rhythms of pituitary hormone secretion (1).

The function of this interface is modified by *feedback*, usually negative, via the nervous system and via the endocrine system.

REGULATION OF ACTH

Cells of Origin

ACTH is released from corticotrophs in the human pituitary, constituting 15-20% of the cells of the anterior pituitary (see Larkin and Ansorge). They are distributed in the median wedge, anteriorly and laterally, and posteriorly adjacent to the pars nervosa. These cells are characteristically identified from their basophil staining and PAS-positivity due to the high glycoprotein content of the N-terminal glycopeptide of pro-opiomelanocortin (*vide infra*), as well as ACTH immunopositivity. Scattered ACTH-positive cells are also present in the human homologue of the intermediate lobe. Some of these appear to extend into the posterior pituitary, so-called "basophilic invasion" (2).

ACTH/POMC

POMC Gene Structure

ACTH is derived from a 266 amino acid precursor, pro-opiomelanocortin (POMC: Figure 1). POMC is encoded by a single-copy gene on chromosome 2p23.3 over 8 kb (3). It contains a 5' promoter and three exons. Apart from the hydrophobic signal peptide and 18 amino-acids of the N-terminal glycopeptide, the rest of POMC is encoded by the 833 bp exon 3.

The POMC Promoter

The promoter of POMC has most extensively been studied in rodents (4). Common transcription elements such as a TATA box, a CCAAT box and an AP-1 site are found within the promoter (5,6). Corticotroph and melanotroph-specific transcription of POMC appears to be dependent on a CANNTG element motif synergistically binding corticotroph upstream transcription element-binding (CUTE) proteins (7). These include neurogenic differentiation 1 factor (NeuroD1) (8), pituitary homeobox 1 (Pitx1 or Ptx1) (9), and Tpit (10,11). NeuroD1 is a member of the NeuroD family and forms heterodimers with other basic-helix-loop-helix (bHLH) proteins, activating transcription of genes that contain an E-box, in this case POMC. This highly restricted pattern of expression in the nervous and endocrine systems is important during development. NeuroD1 is expressed in corticotrophs but not melanotrophs, thus indicating that there are some differences between the

operations of the transcriptional mechanisms of these two POMC-expressing cell types (8). Tpit is a transcription factor of the T-box family and it plays an important role in late-stage cell determination of corticotrophs and melanotrophs (10). Pitx1 is a homeoprotein belonging to a class of transcription factors that are involved in organogenesis and cell differentiation. Both Tpit and Pitx1 bind to their respective responsive elements and are involved in controlling the late differentiation of POMC gene expression, maintaining a basal level of POMC transcription and participating in hormone-induced POMC expression (12). To summarise the respective roles of the CUTE proteins, Pitx1 confers pituitary specificity in the broadest sense, Tpit confers the POMC lineage identity common to corticotrophs and melanotrophs, whereas NeuroD1 expression confers corticotroph identity (4). However, CUTE proteins are not the only method by which POMC expression is differentiated between corticotrophs and melanotrophs. The Pax7 transcription factor has been shown to be a key determinant of melanotroph identity, and it works by remodelling chromatin prior to Tpit expression, opening key areas of chromatin to allow Tpit and other transcription factors access to enhancers, resulting in melanotroph specification (13).

Ikaros transcription factors, which had previously been characterized as being essential for B and T cell development, have been demonstrated to bind and regulate the POMC gene in mice. Moreover, *Ikaros* knockout mice demonstrate impaired corticotroph development in their pituitaries, as well as reduced circulating ACTH, MSH and corticosterone levels (14), suggesting a role in corticotroph development.

POMC transcription is positively regulated by corticotrophin releasing hormone (CRH). CRH acts via its G-protein coupled receptor to activate adenylate cyclase, increase intracellular cAMP and stimulate protein kinase-A (15). Transcription stimulation is mediated by an upstream element (PCRH-RE) binding a novel transcription factor (PCRH-REB) containing protein kinase-A phosphorylation sites (16). CRH also stimulates the transcription of c-Fos, FosB and JunB, as well as binding to the POMC AP-1 site (17). Another secondary messenger pathway that controls POMC expression involves intracellular Ca²⁺ ions (18). Both cAMP and intracellular Ca²⁺ pathways cross-talk with each other (19). These findings further support the importance of cAMP and Ca²⁺ in the intracellular signalling of corticotrophs and melanotrophs. Interestingly, there is a remarkable absence of cAMP-responsive elements (CRE) and Ca²⁺ responsive elements (CaRE) in the promoter region of POMC despite the demonstrated importance of cAMP and Ca²⁺ in the intracellular signalling of corticotrophs and melanotrophs. Other, more indirect strategies have evolved to translate cAMP signals into changes in POMC gene expression involving a CREB/c-Fos/AP-1 signalling cascade activating POMC transcription via an activator protein-1 (AP-1) site in exon 1. Similarly, intracellular Ca²⁺ may signal via the Ca²⁺ binding repressor DREAM (downstream response element-antagonist modulator) and modulation of c-Fos expression (20).

CRH also activates POMC expression through a Nur response element which binds the related orphan nuclear receptors Nur77, Nurr1 and NOR1 (21). The pituitary adenylate cyclase-activating peptide (PACAP) also stimulates cAMP synthesis and POMC transcription, presumably through a common pathway with CRH (22).

The effect of Nuclear transcription factor kappa B (NF- κ B) on POMC expression is unclear. Although NF- κ B is mostly associated with an activation of gene expression, it has been shown to inhibit POMC gene expression by binding to the promoter region (23). In keeping with this finding, CRH treatment is able to block this binding, leading to an increase in POMC expression. In contrary, it has also been shown that more pertinent high glucose (metabolic stress condition) elevates POMC transcription in AtT-20 cells through, or at least in part, the NF- κ B responsive element and AP-1 sites (24). POMC mRNA transcription in corticotrophs is negatively regulated by glucocorticoids (25), although glucocorticoids increase expression of POMC in the hypothalamus (26). The inhibitory effect of glucocorticoids on corticotroph POMC expression appears, in the rat POMC promoter, to be dependent on a glucocorticoid response element partially overlapping the CCAAT box (27). The element binds the glucocorticoid receptor as a homodimer plus a monomer on the other side of the DNA helix (28). Glucocorticoid regulation of corticotroph POMC transcription is also indirectly mediated via other mechanisms such as down-regulation of c-jun expression and direct protein-protein mediated inhibition of CRH-induced AP-1 binding (29), inhibition of CRH receptor transcription (30), inhibition of CRH/cAMP induced activation of Tpit/Pitx1, inhibition of CRH action via the Nur response element (12), and suppression of NeuroD1 expression which in turn inhibits the positive NeuroD1/E-box interaction in the POMC promoter (31).

Leukaemia Inhibitory Factor (LIF), a pro-inflammatory cytokine expressed in corticotrophs, has also been shown to stimulate POMC transcription, via activation of the Jak-STAT pathway (32,33). This stimulation is synergistic with CRH. Deletional analysis of the POMC promoter has identified a LIF-responsive region from –407 to –301. A STAT binding site that stimulates POMC transcription and which partly overlaps with the Nur response element has been identified within the POMC promoter (34). This pathway might form an interface between the immune system and regulation of the pituitary-adrenal axis, particularly during chronic inflammation, where pro-inflammatory cytokines such as LIF might stimulate STAT3 expression and therefore POMC transcription (35). Another interface between the immune system and POMC expression involves Toll-like receptor (most likely TLR4) mediated recognition of lipopolysaccharide, which is a component of the bacterial cell wall. This appears to act via activation of c-Fos and AP-1 expression (36).

The POMC promoter sits within a CpG island, defined as the regions in the genome which the G and C content exceeds 50%. These genomic regions are important controllers of gene expression as hypermethylation of the cytosine leads to silencing of gene expression via remodelling of the chromatin structure to favour heterochromatinization (37). Hypermethylation of the POMC promoter leads to repression of POMC expression in non-expressing tissues. In contrast, hypomethylation leads to de-repression of the POMC promoter in POMC expressing tissues (e.g. corticotrophs). Notably, a small cell lung carcinoma cell line, which expresses POMC and ACTH, possesses a hypomethylated POMC promoter, suggesting that ectopic ACTH secretion by tumours may be due to hypomethylation at a relatively early stage in carcinogenesis (38).

Biogenesis of ACTH

Prohormone convertase enzymes PC1 and PC2 process POMC at pairs of basic residues (Lys-Lys or Lys-Arg). This generates ACTH, the N-terminal glycopeptide, joining peptide, and betalipotropin (beta-LPH) – Figure 1. ACTH can be further processed to generate alpha-melanocyte stimulating hormone (alpha-MSH) and corticotropin-like intermediate lobe peptide (CLIP), whereas beta-LPH can be processed to generate gamma-LPH and beta-endorphin (39). In corticotrophs, POMC is mainly processed to the N-terminal glycopeptide, joining peptide, ACTH and beta-LPH; smaller amounts of the other peptides are present (40). Other post-translational modifications include glycosylation of the N-terminal glycopeptide (41), C-terminal amidation of N-terminal glycopeptide, joining peptide, and alpha-MSH (42,43), and N-terminal acetylation of ACTH, alpha-MSH and beta-endorphin (44,45).

HYPOPHYSIOTROPIC HORMONES AFFECTING ACTH RELEASE

Corticotropin Releasing Hormone (CRH)

This 41 amino-acid neuropeptide (46) is derived from a 196-amino acid prohormone (47). CRH is likely to be involved in all the three types of stress responses; behavioural, autonomic and hormonal. CRH immunoreactivity is mainly found in the paraventricular (PV) nuclei of the hypothalamus, often co-localised with arginine vasopressin (48).

CRH binds to a seven-transmembrane domain receptor (49), which is coupled to adenylate cyclase via $G_{s\alpha}$, stimulating cAMP synthesis and PK-A activity. To date, two CRH receptor genes have been identified in humans (50). CRH-R1 mediates the action of CRH at the corticotroph by binding to both CRH and urocortin I. CRH-R2 also binds to both CRH and urocortin, but with over 20-fold higher affinity for the latter (51). This receptor has been implicated in vasodilation and blood pressure control. CRH secretion is regulated by a number of neurotransmitters and cytokines. These include acetylcholine, norepinephrine, histamine, serotonin, gamma-aminobutyric acid (GABA), interleukin-1 β and tumour necrosis factor. All of these factors increase hypothalamic CRH expression, except for GABA which is inhibitory. Besides stimulating POMC transcription and ACTH biogenesis, CRH stimulates the release of ACTH, leading to a biphasic response with the fast release of a pre-synthesised pool of ACTH, and the slower and sustained release of newly synthesised ACTH (52). Figure 2 describes the stimulation of ACTH release by CRH (53).

Arginine Vasopressin (AVP)

In the anterior pituitary, AVP principally binds to the seven-transmembrane domain V1b receptor, also known as the V3 receptor (54). The receptor is coupled to phospholipase C, phosphatidyl inositol generation and activation of protein kinase-C (55,56) and not via adenylate cyclase and cAMP (15). AVP stimulates ACTH release weakly by itself, but synergises with the effects of CRH on ACTH release (57). Downregulation of protein kinase C by phorbol ester treatment abolishes the synergistic effect of AVP on ACTH release by CRH (58). AVP does *not* stimulate POMC transcription either by itself or in synergism with CRH (59).

The association between AVP and ACTH release suggests that measurement of AVP levels might be useful for assessing anterior pituitary function. However, direct measurement of plasma AVP is technically difficult due to its small molecular size and binding to platelets. Copeptin is a 39-amino acid glycosylated peptide, which is derived from the C-terminal part of the AVP precursor at an equimolar amount to AVP. It remains stable for several days at room temperature in serum or plasma, and its measurement is reliable and reproducible, making it a biomarker of AVP release (60). The copeptin increment during glucagon stimulation testing correlates well with the ACTH increment in healthy controls, but not in patients with pituitary disease (61). Interestingly, there appears to be a sexual dimorphism in terms of the correlation between copeptin and ACTH/cortisol release under the conditions of insulin tolerance testing, with a positive correlation observed in women but no significant correlation in men, i.e. copeptin cannot be used as a universal marker of HPA axis stimulation (62).

Other Influences on ACTH Release

Oxytocin and AVP have been co-localised to the supraoptic and PV nuclei of the hypothalamus (63). Oxytocin controversially inhibits ACTH release in man (64-66) by competing for AVP receptor binding (67), although it may potentiate the effects of CRH on ACTH release (68). A more recent study on monkeys demonstrated that intranasal oxytocin treatment led to a decrease in ACTH release following stress exposure (69). There were no differences observed in the cortisol levels between controls and treatment group, thus suggesting that the attenuation effect of oxytocin on stress response is mediated by ACTH.

Vasoactive intestinal peptide (VIP) and its relative, **peptide histidine isoleucine** (PHI), have been shown to activate ACTH secretion (70). This is most probably mediated indirectly via CRH (71).

Atrial natriuretic peptide (ANP) 1-28 has been localized to the supraoptic and PV nuclei (72). In healthy males, infusion of ANP 1-28 was reported to attenuate the ACTH release induced by CRH (73,74), but this only occurs under highly specific conditions and is not readily reproducible. In physiological doses, ANP 1-28 does not appear to affect CRH-stimulated ACTH release (75).

Opiates and opioid peptides inhibit ACTH release (76). There does not seem to be a direct action at the pituitary level. It is likely that these act by modifying release of CRH at the hypothalamic level (77). Opiate receptor antagonists such as naloxone or naltrexone cause ACTH release by blocking tonic inhibition by endogenous opioid peptides (78).

The endocannabinoid system has recently appeared as a key player in regulating the baseline tone and stimulated peaks of ACTH release. The seven-transmembrane cannabinoid receptor type 1 (CB1) is found on corticotrophs, and the endocannabinoids anandamide and 2arachidonoylglycerol can be detected in normal pituitaries (79). Antagonism of CB1 causes a dosedependent rise in corticosterone levels in mice (80). CB1^{-/-} knockout mice demonstrate higher corticosterone levels compared to wild-type CB1^{+/+} littermates, although the circadian rhythm is preserved. Treatment of the CB1^{-/-} mice with low-dose dexamethasone did not significantly suppress their corticosterone levels and surprisingly caused a paradoxical rise in ACTH levels when compared to the wild-type, although high-dose dexamethasone suppressed corticosterone and ACTH to the same degree in both CB1^{-/-} and CB1^{+/+} mice. These CB1^{-/-} mice have: (1) higher CRH mRNA expression in their PV nuclei; (2) lower glucocorticoid receptor mRNA expression in the CA1 hippocampal region, but not in the dentate gyrus or the PV nucleus; (3) significantly higher baseline ACTH secretion from primary pituitary cell cultures as well as augmented ACTH responses to stimulation with CRH or forskolin (81). It has also been known for some time that the administration of the cannabinoid agonist delta-9-tetrahydrocannabinol (THC) for 14 days suppresses the cortisol response to hypoglycaemia in normal humans (82). Thus, the endocannabinoids appear to negatively regulate basal and stimulated ACTH release at multiple levels of the hypothalamic-pituitary-adrenal axis.

Catecholamines act centrally via alpha₁-adrenergic receptors to stimulate CRH release. Peripheral catecholamines do not affect ACTH release at the level of the pituitary in humans (83).

GH secretagogues such as **ghrelin** and the synthetic GH secretagogue **hexarelin** stimulate ACTH release, probably via stimulating AVP release with a much lesser effect on CRH (84-86).

GH releasing hormone (GHRH) has been shown to potentiate the ACTH and cortisol response to insulin-induced hypoglycaemia, but not to potentiate the ACTH and cortisol response after administration of CRH/AVP (87). **GH-releasing peptide-2** (GHRP-2) has also been shown to cause ACTH release in humans (88,89).

Obestatin, a 23 amino acid amidated peptide, is derived from preproghrelin, which is the same precursor as ghrelin (Figure 3). Obestatin is found to suppress food intake and have opposing metabolic effects to ghrelin when administered intraperitoneally or intracerebrovascularly in mice (90). An early study showed that intravenous or intracerebroventricular obestatin had no effects on pituitary hormone release (GH, prolactin, ACTH and TSH) in male rats (91), consistent with the fact that the obestatin receptor GPR39 is not expressed in the pituitary (90,92,93). A study in mice and non-human primates (baboon) again showed no effects of obestatin on prolactin, LH, FSH and TSH expression and release. However, obestatin was shown to stimulate POMC expression and ACTH release *in vitro* and *in vivo*, and in this study the authors found GPR39 expression in pituitary tissue and primary pituitary cell cultures, contrary to the abovementioned studies. This effect was mediated by the adenylyl cyclase and MAPK pathways. The increase in ACTH release was also associated with an increase in pituitary CRF receptor expression. Interestingly, obestatin did not inhibit the stimulatory effect of ghrelin on ACTH release (94). Therefore, the effects of obestatin on pituitary hormone secretions remain controversial.

Angiotensin II (Ang II) is able to stimulate ACTH release *in vitro* from pituitary cells (95). Central Ang II is likely to stimulate CRH release via its receptors in the median eminence, as passive immunization with anti-CRH can abolish the effect of Ang II (96). Intraventricular Ang II can stimulate ACTH release in rats (97) and is able to stimulate the synthesis of CRH and POMC mRNA (98). Conversely, blockade of Ang II subtype 1 (AT1) receptors with candesartan is able to decrease the CRH, ACTH and cortisol response to isolation stress in rats (99,100). There is some controversy as to whether peripheral Ang II can modulate ACTH secretion. It is likely that the ACTH rise seen after Ang II infusion into rats is mediated via circumventricular organ stimulation, as blockade of Ang II effects on the circumventricular organs with simultaneous infusion of saralasin blocks this rise (97).

In vitro studies have shown an inhibitory effect of **somatostatin** on ACTH release in AtT-20 pituitary cell lines from rats, which is mediated via somatostatin receptor (SSTR) subtypes 2 and 5 (101). This inhibitory effect is dependent on the absence of glucocorticoids in the culture medium, but is more prominent when somatostatin analogues targeting SSTR5 are used (102,103). In rodents, pasireotide, a somatostatin analogue capable of activating SSTR1, 2, 3, and 5 is capable of inhibiting the CRH-stimulated ACTH release in contrast to octreotide (selective for SSTR2 and 5), which was less efficacious (104). Early *in vivo* studies in humans showed no effect of somatostatin on basal or CRH-stimulated ACTH release (105), although somatostatin does decrease basal secretion in the context of Addison's disease (106). It is unlikely, therefore, that somatostatin itself is an inhibitor of ACTH release in normal human physiology. Corticotroph adenomas do express SSTR5 (107) and ACTH secretion from cultured corticotroph adenomas is inhibited by pasireotide (108). This is the basis for the use of pasireotide to treat Cushing's disease (109). Octreotide is clinically ineffective in this context (110).

The role of **TRH** in ACTH release is in dispute. Although there is evidence that prepro-TRH 178-199 can inhibit both basal and CRH-stimulated ACTH release in AtT-20 cell lines and rat anterior pituitary cells (111,112), other investigators have not been able to confirm this (113). There has also been another study showing that TRH is able to induce ACTH release from AtT-20/NYU-1 cells (114), but no *in vivo* studies exist to substantiate a physiological role. **Tumour necrosis factor** α (**TNF** α) is a macrophage-derived pleiotropic cytokine that has been shown to stimulate plasma ACTH and corticosterone secretion in a dose-dependent manner (115). The primary site of action of TNF α effect on the HPA axis is likely to be at the hypothalamic CRHsecreting neurons. The effects are abolished with CRH antiserum treatment, thus suggesting that CRH is a major mediator of the HPA axis response to TNF α .

Interleukins IL-1, IL-6 and possibly IL-2 appear to stimulate ACTH release (116-118), but most of the acute effects of these agents are almost certainly via the hypothalamus (119).

Leukaemia Inhibitory Factor is able to stimulate POMC synthesis, as noted above.

PHYSIOLOGY OF ACTH RELEASE

Pulsatility of ACTH Release

Frequent sampling of ACTH with deconvolution analysis reveals that it is secreted in pulses from the corticotroph with 40 pulses \pm 1.5 measured per 24 hours, on analysis of 10 minute sampling data. These pulses temporally correlate with the pulsed secretion of cortisol, allowing for a 15 minute delay in secretion, and correlate in amplitude (120). Pulse concordance has been measured at 47% (ACTH to cortisol) and 60% (cortisol to ACTH) in one study (121), and 90% (ACTH to cortisol) in another (122). Although the pulsatility of ACTH secretion may result from pulsatile CRH release, there is evidence that isolated human pituitaries intrinsically release ACTH in a pulsatile fashion (123).

Circadian Rhythm

In parallel with cortisol, ACTH levels vary in an endogenous circadian rhythm, reaching a peak between 0600-0900h, declining through the day to a nadir between 2300h-0200h, and beginning to rise again at about 0200-0300h. An increase in ACTH pulse amplitude rather than frequency is responsible for this rhythm (120). The circadian rhythm in glucocorticoid secretion is a key mechanism for re-entraining behaviour in the face of external perturbations such as abrupt phase shift of light conditions, i.e. a model of 'jet lag' (124).

The circadian rhythm is mediated via a master oscillator in the supra-chiasmatic nucleus (SCN). A lesion in the SCN eliminates the glucocorticoid circadian rhythm (125). An autoregulatory negative transcription-translation loop feedback system involving cyclical synthesis of the period proteins Per1-3, Clock/BMAL1 and Cry1/2 acts as the basic molecular oscillator, where the Clock/BMAL1 heterodimer acts to activate the transcription of Per and Cry proteins (the so-called 'positive limb'). In turn, the Per and Cry proteins complex together, translocate back into the nucleus and inhibit Clock/BMAL1-mediated transcription (the so-called 'negative limb'). The system is reset by phosphorylation, ubiquitination and proteasomal degradation of the Per/Cry repressor complexes (126,127). Entrainment of the oscillator is achieved by light input from the retina, mediated via the retinohypothalamic tract. Light-activated transcription of immediate-early genes such as c-fos and JunB (128,129) causes activation of PER1 gene transcription as well as modification of the acetylation pattern of histone tails. The latter are implicated in the control of chromatin structure and accessibility of genes to transcription (130). The impact of a period protein gene deletion on circulating glucocorticoid depends on which side of the clock feedback loop is affected (127). Knockout mice with mutations in the components of positive limb of the oscillator (Clock or BMAL1) suffer from hypocortisolism and lose circadian cyclicity (131,132). The deletion of Per2, which

affects the negative limb of the oscillator, also results in hypocortisolism (133). However, Cry1 knockout (also affecting the negative limb) leads to hypercortisolism (134,135).

Is a circadian rhythm in CRH secretion responsible for the ACTH rhythm? Although there is a report of a circadian rhythm in CRH secretion (136), and in situ hybridization studies show that there is a circadian rhythm in CRH expression in the suprachiasmatic nucleus (137), other reports do not confirm this (138). Moreover, the circadian rhythm persists despite a continuous infusion of CRH, suggesting that other factors are responsible for the modulation of ACTH pulses (139). The most likely alternative candidate is AVP: immunocytochemical studies show a circadian rhythm in AVP expression (140) and *Clock* knockout mice show a loss of the circadian rhythm in AVP RNA expression in the SCN (141).

However, rhythmic HPA axis activity is not the be-all and end-all of the circadian rhythm of glucocorticoid release. For example, the adrenal rhythm of cortisol secretion persists after hypophysectomy (142). Indeed, light pulses can induce glucocorticoid secretion independent of ACTH secretion. This HPA axis-independent pathway is mediated by the sympathetic nervous system innervation of the adrenals (143). The adrenal glands also possess an independent circadian oscillator: oscillatory Clock/BMAL1, Per1-3 and Cry1 expression is seen in the outer adrenal cortex (zona glomerulosa and zona fasciculata). This adrenal circadian clock appears to 'gate' the response to ACTH, i.e. it defines a time window during which ACTH is most able to stimulate glucocorticoid secretion (144). Exogenous ACTH is capable of phase-dependently resetting glucocorticoid rhythms (145), suggesting that the adrenal circadian clock can be entrained by the ACTH rhythm. This illustrates a general principle of circadian system organization, namely that there is a hierarchical system with the SCN master clock entraining and coordinating peripheral and non-SCN tissue clocks via endocrine and neuronal signals.

Stress

Stress, both physical and psychological, induces the release of ACTH and cortisol, particularly via CRH and AVP (146,147), and increases the turnover of these neurohypophysiotropic factors by increasing the transcription of CRH and AVP (148). Recent work has also characterised roles for endogenous nitric oxide (NO) and carbon monoxide (CO) in mediating the ACTH response to stress (149). Neuronal nitric oxide synthase co-localizes with AVP and to some extent CRH in paraventricular neurones (150,151). Knockout mice lacking wild-type and neuronal NO synthase have much reduced quantities of POMC immunoreactivity in their arcuate nuclei and pituitaries compared to wild-type mice (150,152). In general, inflammatory stressors appear to activate an endogenous inhibitory pathway whereby NO and CO attenuate the stimulated secretion of CRH and AVP. These effects can also be seen in terms of circulating AVP. However, the regulation of the pituitary-adrenal axis by other stressors may involve an *activating* role for these gaseous neurotransmitters.

During acute stress, an immediate activation of the autonomic nervous system takes place, followed by a delayed response via the HPA axis-mediated release of glucocorticoids (127). During the initial stage, there is an immediate increase of catecholamines via activation of the sympathetic preganglionic neurons in the spinal cord, which in turn stimulates adrenal medulla production of catecholamines via splanchnic nerve innervation. The catecholamines released will also collectively affect peripheral effector organs where they are translated into the classical *fight-or-flight* response. The delayed response of stress involves activation of the HPA axis, leading to an

increase in glucocorticoid level, which in turn can terminate the effects of the sympathetic response together with the reflex parasympathetic activation. It is important to note that this neurohormonal stress response has an additional endocrine leg in the form of glucagon: together, one of the important effects of this trio is to enhance the release of glucose, amino acids and fatty acids, a coordinated catabolic response to stress (153).

Stress paradigms studied in humans include hypoglycaemia during the insulin tolerance test (Figure 4), and venepuncture (154). Elective surgery has also long been used as a paradigm of the stress response in humans (155-157): the magnitude of cortisol rise correlates positively with the severity of surgery (158). Experimentally, other stress paradigms such as haemorrhage, oxidative stress, intraperitoneal hypertonic saline, restraint/immobilization, foot shock, forced swimming, or shaking are used to study the stress responses in animals. Importantly, different stress paradigms can have differential effects on CRH and AVP. In situ hybridization with intronic and exonic probes can be used to study the transcription of heterogenous nuclear RNA (hnRNA), followed by its processing (including splicing, capping and polyadenylation) to messenger RNA (mRNA) within 1-2 hours. CRH and AVP hnRNA levels in rats subjected to restraint show significant increases at 1 and 2 hours after the induction of stress, followed by significant increases in mRNA levels at 4 hours (159). In contrast, intraperitoneal hypertonic saline causes a rapid 8.6-fold increase in CRH hnRNA and mRNA within 15 minutes, returning to basal levels by 1 hour. AVP hnRNA responses are slower, peaking at 11.5-fold increase by 2 hours, followed by a prolonged elevation of AVP mRNA levels from 4 hours onwards (160). As previously noted, serum copeptin can be used as a more stable biomarker of AVP secretion and copeptin increments correlate well with cortisol secretion in a glucagon stimulation test paradigm (61), but exhibit a sexual dimorphism in the context of the insulin tolerance test (62).

Repetitive stress causes variable effects, enhancement or desensitization, on ACTH responses, depending on the stress paradigm involved. This appears to be positively correlated with changes in AVP binding to V1b receptors, reflecting changes in the number of binding sites and not their affinities. It is at present unclear whether this is due to changes in transcription of the V1b gene, alterations in mRNA stability, translational control or recruitment of receptors from intercellular pools (161).

As noted above, circadian rhythms in adrenal ACTH responsiveness, controlled by local oscillator circuits 'gate' the glucocorticoid output in response to a certain level of ACTH. In the case of stress, this leads to markedly different glucocorticoid responses depending on when (during the active or inactive phase) the experimental stress is applied to experimental animals. Moreover, the timing of repetitive stress application can lead to differences in the behavioural and metabolic responses to repetitive/chronic stress. Lastly, it is also known that stress can influence clock function at the level of the SCN and also at the level of the adrenal circadian oscillator leading to phase shifts (127).

FEEDBACK REGULATION OF THE HPA AXIS

Glucocorticoid feedback occurs at multiple levels: at the pituitary, at the hypothalamus, and most importantly, centrally at the level of the hippocampus, which contains the highest concentration of glucocorticoid receptors in the central nervous system. Multiple effects mediate this feedback (Figure 5), including:

- inhibition of CRH and AVP synthesis and release in the PVN (162,163).
- inhibition of POMC transcription (as outlined above)

• inhibition of ACTH release induced by CRH and AVP (164).

Fast feedback occurs within seconds to minutes and involves inhibition of ACTH release by the corticosteroids, mediated through the glucocorticoid receptor (GR). For example, an injection of prednisolone inhibits ovine CRH-stimulated ACTH release within 20 minutes (165). In vitro this appears to involve inhibition of CRH-stimulated ACTH release, and CRH release, but basal secretion is not affected. Protein synthesis is not required, implying that the glucocorticoid effect is non-genomic (166,167). Cell membrane-associated GR has recently been shown to directly mediate fast feedback inhibition by inhibition of Src phosphorylation in corticotrophs (168), but other work implicates the GC-induced secretion of annexin 1/lipocortin1 from folliculostellate cells as a paracrine mechanism for inhibition of ACTH release (169). Intermediate feedback occurs within 4 hours' time frame and involves inhibition of CRH synthesis and release from CRH neurones, not affecting ACTH synthesis (167). However, it is thought that this is a relatively minor contributor to negative feedback (170). Slow feedback occurs over longer timeframes and involves inhibition of POMC transcription (167), via GR antagonism of Nur response element activation of POMC transcription by CRH. The molecular mechanism involves a GR-dependent recruitment of the histone deacetylase HDAC2 to a trans-repressor complex with Brg1, histone H4 deacetylation and chromatin remodeling (171).

There is evidence that ACTH can inhibit CRH synthesis in the context of elevated CRH levels due to Addison's disease or hypopituitarism, although not in the context of normal human subjects (172). Immunohistochemical studies of the paraventricular nuclei in adrenalectomised or hypophysectomised rats show a reduction of CRH and AVP positive cells when these rats are given ACTH infusions (173).

Glucocorticoids have also been shown to control the cell cycle in corticotrophs. This occurs via feedback repression of the positive cell-cycle regulators L-Myc, N-Myc and E2F2, plus activation of the negative cell-cycle regulators Gadd45 β , GADD45 γ and Cables1. In this way, glucocorticoids negatively regulate corticotroph proliferation, a key influence which appears to be lost in corticotroph adenomas (174).

Eating

Cortisol is well known to rise after eating (175,176). This rise is provoked by two mechanisms: (i) by direct stimulation of the HPA axis; and (ii) via regeneration of cortisone to cortisol by stimulation of $11\Box$ -hydroxysteroid dehydrogenase type 1 (11 β HSD1) (177). There appear to be key differences between the effects of individual macronutrients, where carbohydrates lead to equal stimulation of the HPA axis and 11 β HSD1, and where fat and protein led to greater stimulation of the HPA axis compared to 11 β HSD1.

Direct intravenous infusion of macronutrients such as Intralipid and amino acids does not stimulate cortisol secretion (178,179). The most likely candidates for the factors that mediate stimulation of the HPA axis after eating are the gut hormones which are released in response to enteral nutrients. For example, glucagon-like peptide-1₇₋₃₆ (GLP-1₇₋₃₆) has been shown to stimulate cortisol and ACTH secretion, suggesting a direct effect on the hypothalamus/pituitary (180-182). Gastric inhibitory peptide (GIP), however, has not been shown to stimulate cortisol secretion except in the special case of ectopic GIP receptors in bilateral adrenal hyperplasia, causing food-stimulated Cushing's syndrome (183). 11 HSD1 activity appears to be inhibited by GIP (184), therefore suggesting the GIP is not a key player in mediating the post-prandial rise in cortisol. Although

ghrelin has been shown to increase cortisol secretion when given in infusion (84-86), ghrelin is suppressed after eating, making it an unlikely mediator of the post-prandial cortisol response.

AGING OF THE HPA AXIS

Studies in humans and experimental animals have shown evidence that hyperactivity of the HPA axis contributes to neuronal and peripheral deterioration associated with aging (185,186). Hyperactivity of the HPA axis can be caused by stress and is necessary as part of the physiological adaptation. However, there must be mechanisms to limit the stress response, especially during chronic stress, in order to avoid the damaging effects of prolonged exposure to stress hormones such as CRH and corticosterone.

High basal levels of glucocorticoids and loss of circadian rhythm have been associated with greater cognitive decline at a given age (187). Aging is associated with high basal levels of circulating corticosteroids, although there is not always a correlation between plasma ACTH and corticosteroids (188-190). In addition, there is also an alteration to the circadian rhythm of the HPA axis, as demonstrated by studies using a feeding-associated circadian rhythm paradigm. It was found that it took 1 week for young rats and 3 weeks for older rats to entrain the secretion of corticosterone in response to a restricted feeding schedule where they were fed for 2 hours per day. After the rats were shifted to a different pattern of feeding, the entrained circadian rhythm of corticosterone secretion persisted much longer in young rats than in older rats. This suggests that the aged HPA axis appears to take longer to adjust to changes in circadian rhythm, but such adjustments do not 'stick' as well as compared to the younger HPA axis (191,192).

When the expression of CRH in the SCN was examined using *in situ* hybridization, younger 3-4 month old Sprague-Dawley rats exposed to light from 0400h to 1800h have a clear diurnal rhythm with higher expression seen in samples taken at 0300h versus 2300h. This rhythm was lost in older 17-20 month old rats with equal expression seen in samples from 0300h and 2300h (137). Fetal grafts containing the suprachiasmatic nuclei have been shown to restore the circadian rhythm in old Sprague-Dawley rats, thereby suggesting that the altered diurnal variation of HPA axis probably involves alterations in the function of the suprachiasmatic nuclei (193).

Aging is also associated with increase in expression of 11 HSD1 both in brain and peripheral tissues (194,195). Such changes could conceivably expose tissues to elevated levels of glucocorticoids and contribute to an aging process.

The effects of aging on CRH regulation and whether CRH influences the course of aging are still unclear. Studies have reported increased, unchanged or reduced hypothalamic CRH release and expression during aging (187).

GENDER DIFFERENCES IN THE HPA AXIS REGULATION

Endogenous glucocorticoid responses to stress are significantly elevated (in an oestrogendependent fashion) in females as compared with males (196-199). This oestrogen dependence is likely mediated through oestrogen-response elements within the promoter regions of CRH (200). As previously noted, there is also a sexual differential in the relationship between AVP release and the ACTH/cortisol response during insulin tolerance testing where the serum levels of copeptin (as a marker of AVP release) positively correlate to ACTH/cortisol release in women but not men (62). However, the sexual dimorphism of the stress response is not seen with exercise-induced stress (201) nor acute psychological stress (202).

REGULATION OF THE GH RELEASE Somatotroph Development and Differentiation

Somatotrophs make up approximately 50% of the cell population of the anterior pituitary and generally are concentrated in the lateral wings of the pituitary gland (see <u>Larkin and Ansorge</u>). These cells are characteristically acidophilic, polyhedral and immunopositive for GH and Pit-1. A smaller number of such cells are mammosomatotrophs, i.e. immunopositive for GH and prolactin (203).

During the process of cytodifferentiation in the Rathke's pouch primordium, a cascade of transcription factors is activated to specify anterior pituitary cell types. The two factors particularly involved in differentiation of the lactotroph, somatotroph and thyrotroph lineages are Prop-1 (Prophet of Pit-1) and Pit-1. Prop-1 is a paired-like homeodomain transcription factor; mutations in this gene cause combined GH, prolactin and TSH deficiency. Mutations of Prop-1 will also give abnormalities of gonadotroph function and, occasionally, corticotroph reserve. Interestingly, these deficiciencies are often progressive over time. Pit-1, also known as GHF-1 and Pou1f1, is part of the POU homeodomain family of transcription factors that includes unc-86, Oct-1 and Oct-2 (204). Pit-1 is a key transcription factor that activates GH gene transcription in the somatotroph (*vide infra*).

The transcription factor Foxo1 (forkhead box transcription factor) is expressed in 40% of somatotropes. Foxo1 is involved in the development of various other tissues slow-twitch muscle fibres, bone and pancreas, and a global knockout is lethal. A pituitary-specific knockout of Foxo1 causes a delay in the terminal differentiation of somatotrophs but does not affect commitment of pituitary progenitor cells to the somatotroph lineage (205). Foxo1 exerts its effect via stimulation of NeuroD4 expression which is also important to the terminal differentiation of somatotrophs (206).

GROWTH HORMONE

GH Genomic Locus

Human GH was first isolated in 1956 (207) and the structure of the peptide was elucidated fifteen years later (208). Human GH is a 191 amino acids single chain peptide with two disulphide bonds and molecular weight of 22,000 daltons. The GH locus, a 66 kb region of DNA, is located in chromosome 17q22-q24 and consists of 5 homologous genes, which appear to have been duplicated from an ancestral GH-like gene – Table I (209,210).

Gene	Product	Variant(s)	Expressed in	Notes
hGH-N or GH1	Normal GH	2 alternatively	Anterior pituitary	(211)
		spliced variants		
		(97):		
		22 kDa (full-		
		length 191 aa);		
		20 kDa (lacking		
		residues 32-46)		
hGH-V or GH2	Variant GH	20 kDa	Placental	(214)
	detectable in		syncytiotrophoblast	
	pregnancy from		cells	
	mid-term to delivery			

	(212,213)			
CSH-1, CSH-2	Chorionic	22 kDa	Placental	(215,216)
	somatotropin/human		syncytiotrophoblast	
	placental lactogen		cells	
CSH-like gene	Non-functional	Many		(217)
CSHL-1	proteins	alternatively		
		spliced variants		

Table I: The five genes in the GH locus

Structure of the GH Promoter

Because of their origin from an ancestral GH-like gene, all five genes in the GH genomic locus share 95% sequence identity including their promoters (218): proximal elements in the promoter bind Pit-1/GHF-1 (219-222). Pit-1 plays a central role in controlling the expression of hGH-NN gene. Inactivation or lack of functional Pit-1 expression in both mice and human inhibits the differentiation and proliferation of the pituitary cells (223). Although Pit-1 is necessary for transcription of transfected GH1 genes in rat pituitary cells, it is not sufficient (224). Other transcription factors such as Sp1, CREB, and the thyroid hormone receptor are involved (221,225,226).

A placenta-specific enhancer found downstream of the CSH genes (227) as well as pituitaryspecific repressor sequences found upstream of GH2, CSH-1 and -2, and CSHL-1 may serve to limit transcription of these particular genes to the placenta (228).

A locus control region consisting of two DNase-I hypersensitive regions (HS), specifically HG-I site, 14.5 and 30 kb upstream of GH1 appears to be required for pituitary-specific GH1 expression (229). This region, which also binds Pit-1 (230), activates histone acetyltransferase, which controls chromatin structure and the accessibility of the GH locus to transcription factors (231,232). The acetylated histone domain potentiates GH transcription and more recently, HS-I was also shown to be crucial for establishing a domain of non-coding polymerase II transcription necessary for gene activation (233).

Pit-1 is mainly expressed in the pituitary somatotrophs, but it has also notably been demonstrated to be expressed in extrapituitary tissues. Pit-1 regulates local GH expression in the mammary gland and may be involved in mammary development and possibly the pathogenesis of breast carcinoma (234).

GROWTH HORMONE

This is a 191 amino-acid single chain polypeptide hormone that occurs in various modified forms in the circulation. During spontaneous pulses of secretion the majority full-length isoform of 22 kDa makes up 73%, the alternatively spliced 20 kDa isoform contributes 16%, while the 'acidic' desamido and N-alpha acylated isoforms make up 10%. During basal secretion between pulses other forms (30 kDa, 16 kDa and 12 kDa) can also be identified which consist of immunoreactive fragments of GH (235-237).

Higher molecular weight forms of GH exist in the circulation, representing GH bound to binding proteins or GHBP (238). The high-affinity GHBP consists of the extracellular domain of the hepatic GH receptor, and this binds the 22 kDa GH isoform preferentially (239). This high-affinity GHBP is released into circulation by proteolytic processing of the GH receptor by the metalloprotease

TACE/ADAM-17 (240). The low-affinity GHBP binds the 20 kDa isoform preferentially (241). Binding of GH to GHBP prolongs the circulation time of GH as the complex is not filtered retained by the glomeruli (236). GH/GHBP interactions may also compete for GH binding to its surface receptors (242).

GH is also expressed in other areas of the brain, such as the cortex, hippocampus, cortex, caudate nucleus and retinal areas (243), as is the GH receptor, IGF-I and the IGF-I receptor, where it is thought that these mediate neuroprotective and regenerative functions (244)

HYPOPHYSIOTROPIC HORMONES AFFECTING GH RELEASE

GHRH

GHRH was originally isolated from a pancreatic tumour taken from a patient that presented with acromegaly and somatotroph hyperplasia (245). GHRH is derived from a 108 amino-acid preprohormone to give GHRH(1-40) and (1-44) (Figure 6), which are both found in the human hypothalamus (246,247). The C-terminal 30-44 residues appear to be dispensable, as residues 1-29 show full bioactivity. GHRH binds to a seven-transmembrane domain G-protein coupled receptor that activates adenylate cyclase (248), which stimulates transcription of the GH gene as well as release of GH from intracellular pools (249,250). No other hormone is released by GHRH, although GHRH has homology to other neuropeptides such as PHI, glucagon, secretin and GIP (251).

Somatostatin

Somatostatin (a.k.a. somatotropin release inhibitory factor or SRIF) is derived from a 116 aminoacid prohormone to give rise to two principal forms, somatostatin-28 and -14 (252). Both of these are cyclic peptides due to an intramolecular disulphide bond (Figure 6). Somatostatin has multiple effects on anterior pituitary as well as pancreatic, liver and gastrointestinal function:

- It inhibits GH secretion directly from somatotrophs (253,254) and antagonizes the GH secretagogue activity of ghrelin (255).
- It inhibits GH secretion indirectly via antagonizing GHRH secretion (see Lechan and Toni).
- It inhibits GH secretion indirectly via inhibiting the secretion of ghrelin from the stomach (256-258).
- It inhibits secretion of TSH, and TRH stimulation of TSH secretion from the pituitary (259,260).
- It inhibits the secretion of CCK, glucagon, gastrin, secretin, GIP, insulin and VIP from the pancreas (261).

Somatostatin binds to specific seven-transmembrane domain G-protein coupled receptors (SSTRs), of which there are at least 5 subtypes. SSTR2 and 5 are the most abundant in the pituitary (262). A immunohistochemical study on fetal pituitaries has shown that SSTR2 is present from 13 weeks gestation, mainly on thyrotrophs and gonadotrophs. SSTR5 is mainly found on somatotrophs and develops relatively late in gestation at 35-38 weeks of gestation, suggesting that SSTR2 regulates TSH, LH and FSH whereas SSTR5 regulates GH (263). The somatostatin receptors couple to various 2nd messenger systems such as adenylate cyclase, protein phosphatases, phospholipase C, cGMP dependent protein kinases, potassium, and calcium ion channels (264).

Ghrelin

Ghrelin is an orexigenic (appetite-stimulatory) peptide that was isolated from stomach and can stimulate the release of GH. It is derived from preproghrelin, a 117 amino-acid peptide, by cleavage and n-octanoylation at the third residue to give a 28 amino-acid active peptide (Figure 3 and Figure 6). Ghrelin is the endogenous ligand of the GH secretagogue receptor (GHS-R) 1a, another member of the seven-transmembrane receptor family G-protein coupled to the phospholipase C-phosphoinositide pathway (265,266). This variant of GHS-R has been shown to transduce the GH-releasing effect of synthetic growth hormone secretagogues (GHSs) as well as ghrelin, and also plays a role in neuroendocrine and appetite-stimulating activities centrally. Both ghrelin and GHS-R1a have corresponding widespread tissue expression (267). The other GHS-R variant, GHS-R1b, is a 289 amino acids G-protein coupled receptor with five transmembrane domains. The biological function of GHS-R1b is unclear. It has a widespread expression throughout the body (267) but does not bind to ghrelin or other GHSs. However, it was shown to have counter-regulatory attenuating role on GHS-R1a signalling, possibly via the formation of heterodimers with GHS-R1a (268).

The majority of circulating ghrelin exists as the des-octanoylated (des-acyl) form: octanoylated ghrelin constitutes approximately 1.8% of the total amount of circulating ghrelin (269). Octanoylation appears to be essential for GH secretagogue activity, as des-acyl ghrelin is inactive for GH release (265). The enzyme that octanoylates ghrelin has recently been identified as ghrelin O-acyltransferase (GOAT) (270). GOAT is a porcupine-like enzyme belonging to the super-family of membrane-bound O-acyltransferase 4 (MBOAT4) and has widespread tissue expression corresponding to ghrelin (271). Historically, the earliest GH secretagogues discovered such as GHRP-1, GHRP-2, GHRP-6 and hexarelin were synthetic and derived from enkephalins (272).

In the circulation, ghrelin appears to be bound to a subfraction of HDL particles containing clusterin and the A-esterase paraoxonase. It has been suggested that paraoxonase may be responsible for catalyzing the conversion of ghrelin to des-acyl ghrelin (273). However, inhibition of paraoxonase in human serum does not inhibit the de-acylation of ghrelin, and there is a negative correlation in these sera between the paraoxonase activity and ghrelin degradation. Instead, it is more likely that butyrylcholinesterase and other B-esterases are responsible for this activity (274).

Ghrelin is present in the arcuate nucleus of the hypothalamus and in the anterior pituitary (275). Immunofluoresence studies show that ghrelin is localized in somatotrophs, thyrotrophs and lactotrophs but not in corticotrophs and gonadotrophs, suggesting that ghrelin may be acting in a paracrine fashion in the anterior pituitary (276). It stimulates GH release *in vitro* directly from somatotrophs (265) and also when infused *in vivo*, although the latter action appears to require the participation of an intact GHRH system (255). Ghrelin stimulates GH secretion in a synergistic fashion when co-infused with GHRH (86). Both GHS and ghrelin have been shown to stimulate the release of GH in a dose-related pattern which is more marked in humans than in animals (277,278).

Besides its GH releasing activity, ghrelin has orexigenic activity (279,280), stimulates insulin secretion (281), ACTH and prolactin release (282). Knocking out the preproghrelin gene in mice does not seem to affect their size, growth rate, food intake, body composition and reproduction, indicating that proghrelin products (acyl- or desacyl-ghrelin, obestatin) are not dominantly and critically involved in mouse viability, appetite regulation and fertility (283), although subtle reductions in the amplitude of secretory GH peaks can be detected in these knockout mice during their youth: these differences recede with aging (284). Ghrelin null mice show an increased utilization of fat as an energy substrate when placed on a high-fat diet, which may indicate that

ghrelin is involved in modulating the use of metabolic substrates (285). GHS-R knockout mice have the same food intake and body composition as their wild-type littermates, although their body weight is decreased in comparison. However, treatment of GHS-R null mice with ghrelin does not stimulate GH release or food intake, confirming that these properties of ghrelin are mediated through the GHS-R (286).

Although it is clear that acyl-ghrelin activates GH secretion when injected into mice and men, the specific contribution of acyl-ghrelin to physiological pulsatile GH release is less clear. This question has been studied by knocking out GOAT: these mice showed an overall decline in the amount of GH release compared to age matched wild-type mice. The alteration of the GH release observed did not coincide with alterations in the pituitary GH content and GHRH, somatostatin, neuropeptide Y or GHS-R mRNA expression. However, an increase in pulse number and greater irregularity of GH pulses was observed in these mice. Although other mutations that cause derangement of GH secretion have been previously associated with the 'feminisation' of the expression of GH-dependent sexually divergent liver genes in male animals, there was no evidence of this in the *Goat'*- mice, either as a result of the disordered GH pulse pattern, or because there was a failure of the elevated IGF-1 levels to feedback on GH release. Overall, the data suggest that acyl-ghrelin has a regulatory role in the patterning of GH secretion, but the absence of acyl-ghrelin does not fatally knock out GH production (287).

To complicate things further, des-acyl ghrelin may have biological effects of its own. It has been shown to inhibit apoptosis and cell death in primary cardiomyocyte and endothelial cell cultures (288), to have varying effects on the proliferation of various prostate carcinoma cell lines (289), to inhibit isoproterenol-induced lipolysis in rat adipocyte cultures (290), and to induce hypotension and bradycardia when injected into the nucleus tractus solitarii of rats (291). More controversially, intracerebroventricular or peripherally administered des-acyl ghrelin causes a decrease in food consumption in fasted mice and inhibits gastric emptying. Des-acyl ghrelin overexpression in transgenic mice causes a decrease in body weight, food intake, fat pad mass weight and decreased linear growth compared to normal littermates (292). These observations were not replicated by other researchers, who found no effect of des-acyl ghrelin on feeding (293). The effects of des-acyl ghrelin appear not to be mediated via the type 1a or 1b GHS-R (288-290). The effects of peripherally administered des-acyl ghrelin on stomach motility can be inhibited by intracerebrovascular CRH receptor type 2 antagonists, suggesting that CRH receptor type 2 is involved, but there is no direct evidence that des-acyl ghrelin binds this receptor (294)

As noted above, the GH-stimulatory actions of ghrelin *in vivo* seem to require an intact GHRH system, as immunoneutralisation of GHRH blocks ghrelin-induced GH secretion (255). The actions of GH secretagogues are blocked by hypothalamo-pituitary disconnection, which suggests that *in vivo* ghrelin's stimulatory actions are indirect and mediated by GHRH (295). However, GHRH cannot be the sole mediator of ghrelin's actions as the GH response to ghrelin is greater than that to GHRH (296), and, as noted above, ghrelin synergistically potentiates GH release by a maximal dose of GHRH (86). There is no evidence to suggest that ghrelin decreases somatostatinergic tone as immunoneutralisation of somatostatin does not block ghrelin's ability to release GH (255). There may therefore be another mediator, the so-called 'U' factor, released by ghrelin, which causes GH secretion (297).

Obestatin

As mentioned earlier, the effects of obestatin on pituitary hormones release remain controversial. Initial study has shown that intravenous or intracerebrovascular treatment of obestatin did not affect the release of growth hormone in male rats (91). However, a more recent study has shown that obestatin treatment inhibits both basal and ghrelin-induced GH release and expression, both *in vitro* and *in vivo* in non-human primates and in mice (94). This inhibitory effect is mediated by the adenylyl-cyclase and MAPK pathways. Obestatin treatment causes a reduction in Pit-1 and GHRH-R mRNA levels in the pituitary as well as a decrease in hypothalamic GHRH and ghrelin expression. Obestatin also reduces the expression of pituitary somatostatin receptors, namely SSTR subtypes 1 and 2 (94).

OTHER INFLUENCES ON GROWTH HORMONE RELEASE

Glucocorticoids and Sex Hormones

Glucocorticoid treatment has a biphasic effect on GH secretion: an initial acute stimulation in 3 hours, followed by suppression within 12 hours (298,299). The latter is the clinically important effect, as excess endogenous and exogenous glucocorticoids are well known to suppress growth in children (300). The inhibitory effect of glucocorticoids on GH release is possibly mediated by increase in expression of somatotropin releasing inhibiting factor (SRIF) (301).

Sex hormones are also involved in regulating GH release particularly during puberty and also later in life. They affect GH release by acting at hypothalamic, pituitary and peripheral levels. Both oestrogen and testosterone increase GH secretion in humans by amplifying secretory burst mass and reduce the orderliness of GH secretion (302). Oestrogen affects GH secretion mainly by interacting with the oestrogen receptor a expressed in the GHRH neurons and in the GH-secreting pituitary cells. The stimulatory effects of oestrogen on GH secretion are possibly mediated by the release of GHRH and/or by enhancing the sensitivity to ghrelin released from the hypothalamus (303). Oestrogen increases the irregularity in pulsatility and lowering total and free IGF-I. Although oestrogen increases the secretion of GH, it is also known to counter-regulate itself by reducing GH sensitivity in the liver, hence decreasing the secretion of IGF-I. GH deficient patients started on oestrogen therapy therefore require a higher dose of GH replacement therapy to achieve a particular target IGF-I level (304). The route of oestrogen replacement is an important influence on GH requirement and those on oral oestrogen are clearly more GH resistant than women using transdermal preparations (305,306). Testosterone, on the other hand, increases basal GH secretion and IGF-I concentrations, thus relieving the negative feedback on the GH secretion (302).

Leptin

Leptin is a 167 amino-acid anorexigenic peptide primarily produced by white adipose tissue (307), regulates body fat mass (308) by feedback inhibition of the appetite centres of the hypothalamus (309). Leptin and its receptor have been detected both by RT-PCR and immunohistochemistry in surgical pituitary adenoma specimens and in normal pituitary tissue (310,311). However, pituitary adenoma cells in culture do not secrete GH in response to leptin treatment (311,312).

Leptin increases GH secretion in the short term, mainly via an increase in GHRH secretion and decrease in SRIF expression. In the long term, it leads to a decrease in GH secretion, probably reducing GHRH sensitivity (313). In obese subjects, in whom which plasma leptin levels are persistently elevated, GH secretion and responsiveness are reduced in both animals and humans (314). However, if leptin-deficient obese subjects are studied in parallel with sex and BMI-matched

leptin-replete obese subjects, it is found that their GH responses to GHRH and GHRP-6 are equally blunted suggesting that the leptin is not influential in mediating the hyposomatotropinism of obesity (315).

Kisspeptin

Kisspeptin is a peptide hormone that binds to the G-protein coupled receptor GPR54. Although it was originally characterized as a 'metastasis suppressor' gene, its most well-characterised role in in stimulating the secretion of GnRH from GnRH neurones, in turn leading to gonadotropin production from pituitary gonadotrophs. In addition to this, kisspeptin stimulates GH release from somatotrophs (316,317). These positive effects of kisspeptin are seen when given in vivo to cows or sheep (318), but so far have not been seen when given intravenously in small studies in human volunteers (319), although this may be because the GH stimulatory effects are only observed with central administration.

Catecholamines

In general, alpha-adrenergic pathways stimulate GH secretion, by stimulation of GHRH release and inhibition of somatostatinergic tone, while beta-adrenergic pathways inhibit secretion by increasing somatostatin release (320,321). The alpha₂-adrenoceptor agonist clonidine can therefore be used as a provocative test of GH secretion (322,323) although clinical experience suggests that this is an unreliable stimulatory test for GH secretion in practice. L-dopa stimulates GH secretion; however, this action does not appear to be mediated via dopamine receptors as specific blockade of these receptors with pimozide does not alter the GH response to L-dopa (324). Instead, L-dopa's effects appear to depend on conversion to noradrenaline or adrenaline, as α -adrenoceptor blockade with phentolamine disrupts the GH response to L-dopa (325).

Acetylcholine

Muscarinic pathways are known to stimulate GH secretion, probably by modulating somatostatinergic tone (326). Pyridostigmine, an indirect agonist which blocks acetylcholinesterase, increases the 24 hour secretion of GH by selectively increasing GH pulse mass (327). On the other hand, the muscarinic antagonist atropine is able to blunt the GH release associated with slow wave sleep (328) and that associated with GHRH administration (329). Passive immunization with anti-somatostatin antibodies abolishes the pyridostigmine induced rise in GH in rats, but not immunization with anti-GHRH antibodies, supporting the central role of somatostatinergic tone in mediating this response (330).

Dopamine

Continuous infusion of dopamine into normal healthy men leads to an increase in mean GH secretion comparable to that observed with GHRH. When given together, dopamine and GHRH have additive effects on GH secretion, and similarly the dopamine agonist bromocriptine augments the effects of GHRH (331).

Endogenous opioids

Endorphins and enkephalins are able to stimulate GH secretion in man (332), and blockade with opiate antagonists can attenuate the GH response to exercise (333). Passive immunization against GHRH in rats inhibits GH release in response to an enkephalin analogue, which argues for stimulation of GHRH in response to these compounds (334). In keeping with this, a recent study

demonstrated close juxtapositions between the enkephalinergic/ endorphinergic/ dynorphinergic axonal varicosities and GHRH-immunoreactive perikarya in the human hypothalamus (335). Morphologically, majority of contacts between the GHRH perikarya and endogenous opiates were enkephalinergic while only few dynorphin- and endorphin-GHRH interactions were detected. Enkephalinergic-GHRH interactions and fibers are known to be densely populated in the infundibular nucleus and anterior periventricular area, thereby suggesting that enkephalin regulates not only the activity of GHRH- but also somatostatin-synthesizing neurons (336). The balance between the activation of GHRH and somatostatin neuronal systems may determine if enkephalin stimulates or inhibits or have no effect on pituitary GH secretion. Unfortunately, the study was unable to detect for presence of synapses between the enkephalinergic/ endorphinergic/ dynorphinergic and GHRH neurons because the immunocytochemistry was carried out under light microscope. Electron microscopy was not applied in the study due to the long post mortem period. Nevertheless, these findings demonstrated the presence of intimate associations between the endogenous opiate and the GHRH systems in the human hypothalamus, as well as indicated the significant differences between the regulatory roles of endogenous opiates on growth in human.

Stimulation of GHRH by endorphins and enkephalins cannot be the only mechanism increasing GH release, however, as the met-enkephalin analogue DAMME is able to increase GH release over and above the levels released during maximal stimulation by a GHRH analogue (337). It is possible that the actions of endogenous opioids occur via an interaction with the GHS-R, as the original GH secretagogues characterised were derived from the enkephalins (272).

Endocannabinoids

As with ACTH/cortisol, the endocannabinoids may also influence the release of GH. Somatotroph cells bear the CB1 receptor (79). The administration of THC for 14 days suppresses the GH secretion in response to hypoglycaemia in healthy human subjects (82). Oddly enough, THC and anandamide appear to have opposed effects on GH levels in ovariectomized rats: THC increases and anandamide decreases GH secretion in this context (338). However, the treatment of anterior pituitary cells in primary culture with THC does not seem to influence the release of GH and prolactin to GHRH and TRH, suggesting that the effects of THC are mediated via the hypothalamus and not directly on the anterior pituitary (339), perhaps by stimulating somatostatin release (340).

Ghrelin and the Endocannabinoid System

Ghrelin and the endocannabinoid system interact in a bidirectional fashion. The intraperitoneal administration of cannabinoids results in increased plasma ghrelin levels and stomach ghrelin expression in rats (341) and CB1 receptor antagonism with rimonabant reduces ghrelin levels (342), suggesting that the orexigenic effects of cannabinoids may also be connected to an increase in ghrelin secretion from the gastric X/A-like cells. The effects of ghrelin on appetite were also abolished in CB1 knockout or in the presence of the CB1 antagonist rimonabant (343-345). In addition, the effects of cannabinoids are also abolished in the absence of the ghrelin receptor GHS-R1a (346). These findings confirm that both ghrelin and cannabinoid signaling pathways have to be intact to mediate the effects of these two systems on appetite. Interestingly, *in vivo* and *in vitro* GH release is intact in response to ghrelin in CB1-knockout animals (344). These findings are intriguing because they suggest that the effects of ghrelin on GH release are somehow modulated differently at the receptor-binding stage of the pathway compared to its orexigenic and metabolic effects. Moreover, it has also been proposed that the bidirectional relationship of the ghrelin and endocannabinoid system might be potentially mediated by the interaction (e.g. heterodimerisation) between GHS-R1a and CB1 receptors (346). However, further molecular and

functional studies are needed to elucidate the exact mechanism of interaction between these two systems.

Other Neuropeptides and Factors Affecting GH Secretion

Many neuropeptides, including the ones in the following paragraphs, have been shown to influence GH secretion in various contexts. For the most part, however, their physiological role in man is not well characterised.

Infusion of **galanin**, a 29 amino-acid peptide originally isolated from the small intestine, causes stimulation of GH secretion when infused alone and also enhances GHRH-stimulated GH secretion (347).

Calcitonin, the 32 amino-acid peptide secreted from the C cells of the thyroid gland, appears to inhibit the stimulated secretion of GH by arginine and insulin-induced hypoglycaemia (348,349).

Neuropeptide Y (NPY) is an orexigenic peptide that has been shown to inhibit GH secretion in rats (350-352), from human somatroph tumour cells in culture (353), and from rat hypothalamic explants (354). When infused into patients with prolactin-secreting pituitary adenomas, 9 out of 15 patients showed a paradoxical rise in GH levels (355). However, when infused into healthy young men overnight, NPY did not have any significant effect on GH secretion (356).

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a hypothalamic C-terminally amidated 38 residue peptide hormone originally characterised on the basis of its ability to stimulate cAMP accumulation from anterior pituitary cells (357). In rats, PACAP stimulates GH release from pituitary cell lines and also when infused *in vivo* (358-360). When infused into human volunteers, however, GH levels do not appear to be affected (361).

Klotho, a transmembrane protein that is classically known for its 'co-receptor' activity with fibroblast growth hormone receptors, has recently been characterized as a possible secretagogue for GH. Although it is usually attached to membranes, the extracellular region can be shed from the cell surface, and there is some evidence for endocrine activity. Klotho knockout mice exhibit reduced growth in the context of a 'early aging' phenotype, and histophatological examination of their somatotrophs demonstrate reduced numbers of secretory granules. Klotho treatment of somatotrophs in vitro has been demonstrated to increase GH secretion, but at present its physiological role is yet to be fully elucidated (362).

FEEDBACK LOOPS OF GH SECRETION

Multiple negative feedback loops exist to autoregulate the GH axis (Figure 7).

- Somatostatin auto-inhibits its own secretion (363).
- GHRH auto-inhibits its own secretion by stimulating somatostatin release (364).
- **GH** auto-regulates its own secretion in short term by stimulating somatostatin release and inhibiting GHRH-stimulated GH release (365-367). There is also a negative feedback on stomach ghrelin release by GH (368). More recently, it is demonstrated that in long term feedback situation, the inhibition of GH release is most likely due to feedback inhibition by IGF-I (369).
- **IGF-I**, whose production is stimulated by GH, inhibits GH release in a biphasic manner: (1) by stimulating hypothalamic somatostatin release early, and (2) by inhibiting GH release

after 24 hours, probably by inhibiting GH mRNA transcription (370,371). Interestingly, IGF-I infusion suppresses GHRH induced GH release in males but not in females, suggesting a sexually dimorphic effect (369).

PHYSIOLOGY OF GH SECRETION

Pulsatility of GH Secretion

The secretory pattern of GH was first elucidated in rats (372). Circulating GH levels are pulsatile, with high peaks separated by valleys where the GH is undetectable by conventional RIAs or IRMAs (Figure 8). The recent development of sensitive chemiluminescent assays for GH with high frequency sampling and deconvolution analysis has allowed the detailed study of GH secretion. This shows that there are detectable levels of basal GH secretion in the 'valleys' (373). On average, there are 10 pulses of GH secretion per day lasting a mean of 96.4 mins with 128 mins between each pulse (374). The diurnal secretory pattern of GH in human is fully developed after puberty, demonstrating a major peak at late night/early morning which is associated with the REM-sleep, and a number of peaks during the light hours of the day, but with quite large individual difference (375).

There is a dynamic interplay of pulsatile GHRH and somatostatin secretion:

- Via crosstalk: GHRH neurones receive inhibitory inputs from somatostatin neurons, whilst somatostatin neurones receive direct stimulatory inputs from GHRH neurones (see <u>Lechan</u> and <u>Toni</u>).
- Via synergistic actions on somatotrophs: Pre-exposure to somatostatin enhances GHRH-stimulated secretion of GH (376).

Further studies in animals have revealed that somatotropin releasing inhibiting factor regulates the magnitude of the troughs of GH as well as the amplitude of the peaks, whereas GHRH functions as the main regulator of the pulsatile pattern (369,377,378). Interestingly, continuous GHRH administration in human volunteers does not affect the pulsatility of GH secretion (379). Moreover, patients with an inactivating mutation of the GHRH receptor continue to show pulsatile GH secretion, suggesting that somatostatin pulsatility is sufficient to determine GH pulsatility (380). These observations suggest that the mechanisms involved in human may differ from the animal models.

GH AND Sexual Dimorphism

The technical developments in sensitive detection of GH and deconvolution analysis referred to above have elucidated differences in secretion between men and women. Women have higher mean GH levels throughout the day than men due to higher incremental and maximal GH peak amplitudes (Figure 8), but show no significant difference in GH half-life, interpulse times or pulse frequency (381). The higher basal GH levels may underlie the higher nadir GH levels seen in normal women after GH suppression with oral glucose (382). Recent evidence suggests that there are sexual differences in the expression of somatostatin and somatostatin receptor subtypes in the rat pituitary, which would clearly cause differences in the physiological regulation of GH release (383).

Differences in GH secretion patterns between the sexes, with male 'pulsatile' secretion versus female 'continuous' secretion, can cause different patterns of gene activation in target tissues, e.g. induction of linear growth patterns, gain of body weight, induction of liver enzymes and STAT 5b signalling pathway activity (384).

GH and Aging

GH and IGF-I levels are known to decline continuously with age and to very low levels in those aged \geq 60 years (385). This phenomenon, known as 'somatopause', is also seen in other mammals and has led to the speculation that GH treatment can be a potent anti-aging therapy (386). Conversely, decreased GH/IGF-I signaling has also been shown to extend longevity in a wide variety of species such as worms, fruit flies, mice and yeast (387), thus raising the question of whether decreased activity of GH/IGF-I axis might be beneficial for human longevity. Somatopause might therefore be nature's way of sustaining the aging individual (388).

It is also suggested that the anorexia associated with aging is due to the decline in the level of acylated ghrelin in older adults. This is supported by a recent study that showed an age-dependent decline in both circulating acyl-ghrelin and growth hormone levels in older adults (aged 62-74 years, BMI range 20.9-29 kg/m²) compared to young adults (aged 18-28 years, BMI range 20.6-26.2 kg/m²) (389). By estimating the correlations between amplitudes of individual GH secretory events and the average acyl-ghrelin concentration in the 60-minute interval preceding each GH burst, the ghrelin/GH association was more than 3-fold lower in the older group compared with the young adults, thus suggesting that with normal aging, endogenous acyl-ghrelin levels are less tightly linked to the GH regulation. In addition, ghrelin mimetics have also been shown to be a potential treatment for the musculoskeletal impairment associated with aging (390).

Sleep

The secretion rate of GH shows a circadian pattern, with peak rates measured during sleep. These are approximately triple the daytime rate (391). GH secretion is especially associated with slow wave sleep (SWS – stages 3 and 4) (392). The decline in GH secretion during aging is paralleled by the decreasing proportion of time spent in SWS, although it is unclear which is cause and which is effect (393). In early data from a clinical trial, GH deficient patients have increased sleep fragmentation and decreased total sleep time, and it is conjectured that such alterations in sleep patterns may be responsible for excessive daytime sleepiness in such patients (394).

Sleep deprivation, in the laboratory or due to travel causing 'jet lag', causes two alterations in the GH secretory pattern: the magnitude of secretory spikes is augmented: the return to pre-travel levels takes at least 11 days and is slower to recover after westward travel. The major pulse of GH secretion occurring in early sleep is also shifted to late sleep (395).

Adminstration of a GHRH antagonist reduces the nocturnal GH pulsatility by 75% (396). Normal subjects remain sensitive to GHRH boluses during the night, however, and the lowering of somatostatinergic tone during the night may be responsible for the increase in GH secretion rate (397). Recent work, however, has also demonstrated that ghrelin levels rise through the night in lean men (398). It is likely, therefore, that a combination of increased GHRH, decreased somatostatin and increased ghrelin levels underlie the circadian variation in GH secretion.

Administration of GHRH augments the increased nocturnal GH release and promotes SWS. Somatostatin does not change nocturnal GH release, does not affect the proportion of SWS but may increase rapid eye movement (REM) sleep density (399). Ghrelin has been shown to promote slow wave sleep at the expense of REM sleep, accompanied by an increase in GH and prolactin release when administered exogenously (400).

Exercise

Exercise is a powerful stimulus to secretion of GH (401), which occurs by about 15 min from the start of exercise (402). The kinetics may vary between subjects, an effect which is likely to be related to differences in age, sex and body composition (403). Ten minutes of high-intensity exercise is required to stimulate a significant rise in GH (404). Anaerobic exercise causes a larger release of GH than aerobic exercise of the same duration (405). Acetylcholine, adrenaline, noradrenaline and endogenous opioids have been implicated in exercise-induced GH release (326). However, ghrelin levels do not rise in acute exercise, indicating that ghrelin may not have a role to play in exercise-induced GH release (406).

Hypoglycaemia

Insulin-induced hypoglycaemia is another powerful stimulus to GH secretion (Figure 9) (407,408). The peak GH levels achieved during insulin stress testing correlate well with those achieved during slow wave sleep (409). The hypoglycaemic response is mediated by \Box_2 -adrenergic receptors (410) to cause inhibition of somatostatin release (326), although other evidence argues for a role of stimulated GHRH release, as a GHRH receptor antagonist significantly suppressed hypoglycaemic GH release (411). Ghrelin is unlikely to be involved in the GH response to insulin-induced hypoglycaemia as ghrelin levels are suppressed by the insulin bolus (412).

Other stressors

Other physical stresses such as hypovolaemic shock (413) and elective surgery (414) cause increased GH release. α -adrenergic dependent mechanisms are thought to underly this, as blockade with phentolamine inhibits the response (414).

Hyperglycaemia

In contrast to hypoglycaemia, ingestion of an oral glucose load causes an initial suppression of plasma GH levels for 1-3 hours (Figure 10), followed by a rise in GH concentrations at 3-5 hours (415). The initial suppression could be mediated by increased somatostatin release as pyridostigmine, a postulated inhibitor of somatostatin release, blocks this suppression (416). Circulating ghrelin levels also fall following ingestion of glucose (417). The GH response to ghrelin and GHRH infusions is blunted by oral glucose, an effect that is probably mediated by somatostatin (418). The later rise in GH levels is postulated to be due to a decline in somatostatinergic tone plus a reciprocal increase in GHRH, leading to a 'rebound' rise (326).

In type I diabetes mellitus, GH dynamics are disordered, with elevated 24 hour release of GH (419). Deconvolution analysis shows that GH pulse frequencies and maximal amplitudes are increased. The latter is accounted for by higher 'valley' levels (420). Better glycaemic control appears to normalize these disordered dynamics (421). The pathophysiological mechanism appears to involve reduced somatostatinergic tone (326).

There is conflicting evidence for increased, decreased or normal GH dynamics in type II diabetics. It is likely that this reflects two factors acting in opposite directions: (1) the confounding factor of obesity in these patients, which leads to hyposecretion of GH; and (2) the hyperglycaemia, which leads to hypersecretion (326).

Dietary Restriction and Fasting

Dietary restriction and fasting lead to a significant increase in pituitary secretion of GH (422). A 5day fast in normal healthy men resulted in a significant increase in the pulse frequency as well as pulse amplitude of GH release. This was coupled with a decrease in expression and secretion of IGF-I, which could explain the lack of feedback inhibitory effect on pituitary GH secretion in the fasting state.

Obesity and malnutrition

Chronic malnutrition states such as marasmus and kwashiorkor cause a rise in GH levels (423). On the other hand, obesity is known to be associated with lower GH levels, partially due to decreased levels of GH binding protein and partially due to decreased frequency of GH pulses (424). Visceral adiposity, as assessed by CT scanning and dual energy X-ray absorptiometry, seems to be especially important, and correlates negatively with mean 24 hour GH concentrations (425). The mechanism of decreased GH release in obesity has been ascribed to increased somatostatinergic tone, as pyridostigmine is able to reverse this, to some extent, by suppressing somatostatin release (426-428). However, this cannot be the full explanation, as pyridostigmine is not able to fully reverse the hyposomatotropinism of obesity, even when combined with GHRH and the GH secretagogue GHRP-6 (429).

The fasting induced elevation in secretion of GH is blunted in obesity (430,431). Nevertheless, fasting in obese volunteers still induces an appreciable increase in GH secretion, with accompanying increase in lipolysis and insulin resistance. Co-administration of pegvisomant (a GH receptor antagonist) abrogated this phenomenon, suggesting that the elevation in GH during fasting is responsible for the insulin resistance induced by fasting (432).

Although leptin has been shown to be influential on GH secretion in rats (433), this may not be so in humans. Leptin-deficient subjects have been compared with obese non-deficient control subjects in their GH responses when stimulated with GHRH plus GHRP-6. Both these groups have decreased GH peaks compared to non-obese control subjects, as expected. There was no significant difference in mean GH peaks between leptin-deficient and leptin-replete controls, suggesting that leptin does not play a significant role in the GH suppression seen in obese humans, and that the decreased GH secretion of obesity is mediated via other mechanisms (315).

Another candidate for the mechanism linking obesity to GH secretion is ghrelin. Its levels correlate negatively with body fat content (434). A comparative study between 5 lean and 5 obese men employed rapid sampling and pulse analysis of ghrelin levels over 24 hours. Ghrelin levels increased at night in the lean controls but did not in the obese group (398). Weight loss caused circulating ghrelin levels to rise in two studies (435,436). Contradicting this, however, Lindeman and colleagues found that ghrelin levels paradoxically correlated positively with visceral fat area, in contrast with 24 hour GH secretion, which correlated negatively. Moreover, in their study, weight loss increased GH secretion but did not affect ghrelin levels (437). The response of GH secretion to exogenous ghrelin is significantly blunted in obese patients and this response is restored early on after Roux-en-Y gastric bypass (prior to any major weight loss), suggesting that there is an intrinsic resistance to ghrelin in obesity which is reversed with gastric bypass, and which is not linked to weight loss (438). Therefore, there does not appear to be a simple relationship where obesity-induced reduction in ghrelin levels leads to the reduced secretion of GH.

Amino Acids

GH release is stimulated by a protein meal (439). L-arginine, an essential amino acid, can be used as a provocative test for GH secretion (440). Evidence that L-arginine acts through inhibition of somatostatin release includes the observation that L-arginine can still enhance the GH response to GHRH despite the use of maximal doses of GHRH (441). However, a specific GHRH antagonist blunted the GH response to L-arginine, an observation that supports the notion that L-arginine also acts through stimulation of GHRH secretion (411). Unlike oral glucose, L-arginine does not modify the GH response to ghrelin infusion (418).

REFERENCES

- Marshall J. Control of Pituitary Hormone Secretion Role of Pulsatility. In: Besser G, Thorner M, eds. Comprehensive Clinical Endocrinology. Edinburgh, UK: Mosby; 2002:19-34.
- 2. Doniach I. Histopathology of the pituitary. Clin Endocrinol Metab 1985; 14:765-789
- McKusick V, Phillips JI, Hamosh A, Tiller G, O'Neill M. Pro-opiomelanocortin. In: McKusick V, ed. Online Mendelian Inheritance in Man. Baltimore, MD, USA: Johns Hopkins University; 2007: <u>http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176830</u>. Accessed 20 Jan 2007
- 4. Drouin J. 60 YEARS OF POMC: Transcriptional and epigenetic regulation of POMC gene expression. J Mol Endocrinol 2016; 56:T99-T112
- **5.** Drouin J, Chamberland M, Charron J, Jeannotte L, Nemer M. Structure of the rat proopiomelanocortin (POMC) gene. FEBS Lett 1985; 193:54-58
- **6.** Therrien M, Drouin J. Pituitary pro-opiomelanocortin gene expression requires synergistic interactions of several regulatory elements. Mol Cell Biol 1991; 11:3492-3503
- **7.** Therrien M, Drouin J. Cell-specific helix-loop-helix factor required for pituitary expression of the pro-opiomelanocortin gene. Mol Cell Biol 1993; 13:2342-2353
- 8. Poulin G, Turgeon B, Drouin J. NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol 1997; 17:6673-6682
- **9.** Lamonerie T, Tremblay JJ, Lanctot C, Therrien M, Gauthier Y, Drouin J. Ptx1, a bicoidrelated homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Genes Dev 1996; 10:1284-1295
- **10.** Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 2001; 104:849-859
- **11.** Langlais D, Couture C, Sylvain-Drolet G, Drouin J. A Pituitary-Specific Enhancer of the POMC Gene with Preferential Activity in Corticotrope Cells. Molecular endocrinology 2011; 25:348-359
- **12.** Murakami I, Takeuchi S, Kudo T, Sutou S, Takahashi S. Corticotropin-releasing hormone or dexamethasone regulates rat proopiomelanocortin transcription through Tpit/Pitx-responsive element in its promoter. J Endocrinol 2007; 193:279-290
- **13.** Budry L, Balsalobre A, Gauthier Y, Khetchoumian K, L'Honore A, Vallette S, Brue T, Figarella-Branger D, Meij B, Drouin J. The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling. Genes Dev 2012; 26:2299-2310
- **14.** Ezzat S, Mader R, Yu S, Ning T, Poussier P, Asa SL. Ikaros integrates endocrine and immune system development. J Clin Invest 2005; 115:1021-1029
- **15.** Aguilera G, Harwood JP, Wilson JX, Morell J, Brown JH, Catt KJ. Mechanisms of action of corticotropin-releasing factor and other regulators of corticotropin release in rat pituitary cells. J Biol Chem 1983; 258:8039-8045
- **16.** Jin WD, Boutillier AL, Glucksman MJ, Salton SR, Loeffler JP, Roberts JL. Characterization of a corticotropin-releasing hormone-responsive element in the rat proopiomelanocortin gene promoter and molecular cloning of its binding protein. Molecular endocrinology 1994; 8:1377-1388
- **17.** Autelitano DJ, Cohen DR. CRF stimulates expression of multiple fos and jun related genes in the AtT-20 corticotroph cell. Mol Cell Endocrinol 1996; 119:25-35

- **18.** Loeffler JP, Kley N, Pittius CW, Hollt V. Calcium ion and cyclic adenosine 3',5'monophosphate regulate proopiomelanocortin messenger ribonucleic acid levels in rat intermediate and anterior pituitary lobes. Endocrinology 1986; 119:2840-2847
- **19.** Antoni FA. Interactions between intracellular free Ca2+ and cyclic AMP in neuroendocrine cells. Cell Calcium 2012; 51:260-266
- **20.** Jenks BG. Regulation of proopiomelanocortin gene expression: an overview of the signaling cascades, transcription factors, and responsive elements involved. Ann N Y Acad Sci 2009; 1163:17-30
- **21.** Martens C, Bilodeau S, Maira M, Gauthier Y, Drouin J. Protein-protein interactions and transcriptional antagonism between the subfamily of NGFI-B/Nur77 orphan nuclear receptors and glucocorticoid receptor. Molecular endocrinology 2005; 19:885-897
- **22.** Boutillier AL, Monnier D, Koch B, Loeffler JP. Pituitary adenyl cyclase-activating peptide: a hypophysiotropic factor that stimulates proopiomelanocortin gene transcription, and proopiomelanocortin-derived peptide secretion in corticotropic cells. Neuroendocrinology 1994; 60:493-502
- 23. Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C. NF-kappaB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem 2004; 279:10837-10840
- 24. Asaba K, Iwasaki Y, Asai M, Yoshida M, Nigawara T, Kambayashi M, Hashimoto K. High glucose activates pituitary proopiomelanocortin gene expression: possible role of free radical-sensitive transcription factors. Diabetes Metab Res Rev 2007; 23:317-323
- 25. Suda T, Tozawa F, Yamada M, Ushiyama T, Tomori N, Sumitomo T, Nakagami Y, Demura H, Shizume K. Effects of corticotropin-releasing hormone and dexamethasone on proopiomelanocortin messenger RNA level in human corticotroph adenoma cells in vitro. J Clin Invest 1988; 82:110-114
- **26.** Wardlaw SL, McCarthy KC, Conwell IM. Glucocorticoid regulation of hypothalamic proopiomelanocortin. Neuroendocrinology 1998; 67:51-57
- 27. Drouin J, Charron J, Gagner JP, Jeannotte L, Nemer M, Plante RK, Wrange O. Proopiomelanocortin gene: a model for negative regulation of transcription by glucocorticoids. J Cell Biochem 1987; 35:293-304
- **28.** Drouin J, Sun YL, Chamberland M, Gauthier Y, De Lean A, Nemer M, Schmidt TJ. Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. Embo J 1993; 12:145-156
- **29.** Autelitano DJ, Lundblad JR, Blum M, Roberts JL. Hormonal regulation of POMC gene expression. Annu Rev Physiol 1989; 51:715-726
- **30.** Pozzoli G, Bilezikjian LM, Perrin MH, Blount AL, Vale WW. Corticotropin-releasing factor (CRF) and glucocorticoids modulate the expression of type 1 CRF receptor messenger ribonucleic acid in rat anterior pituitary cell cultures. Endocrinology 1996; 137:65-71
- **31.** Parvin R, Saito-Hakoda A, Shimada H, Shimizu K, Noro E, Iwasaki Y, Fujiwara K, Yokoyama A, Sugawara A. Role of NeuroD1 on the negative regulation of Pomc expression by glucocorticoid. PloS one 2017; 12:e0175435
- Ray DW, Ren SG, Melmed S. Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 1996; 97:1852-1859
- **33.** Ray DW, Ren SG, Melmed S. Leukemia inhibitory factor regulates proopiomelanocortin transcription. Ann N Y Acad Sci 1998; 840:162-173
- **34.** Mynard V, Guignat L, Devin-Leclerc J, Bertagna X, Catelli MG. Different mechanisms for leukemia inhibitory factor-dependent activation of two proopiomelanocortin promoter regions. Endocrinology 2002; 143:3916-3924

- **35.** Bousquet C, Zatelli MC, Melmed S. Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. J Clin Invest 2000; 106:1417-1425
- **36.** Iwasaki Y, Taguchi T, Nishiyama M, Asai M, Yoshida M, Kambayashi M, Takao T, Hashimoto K. Lipopolysaccharide stimulates proopiomelanocortin gene expression in AtT20 corticotroph cells. Endocr J 2008; 55:285-290
- **37.** Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nature reviews Genetics 2013; 14:204-220
- **38.** Newell-Price J, King P, Clark AJ. The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression. Molecular endocrinology 2001; 15:338-348
- **39.** Benjannet S, Rondeau N, Day R, Chretien M, Seidah NG. PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc Natl Acad Sci U S A 1991; 88:3564-3568
- **40.** Chretien M, Seidah NG. Chemistry and biosynthesis of pro-opiomelanocortin. ACTH, MSH's, endorphins and their related peptides. Mol Cell Biochem 1981; 34:101-127
- **41.** Seidah NG, Chretien M. Complete amino acid sequence of a human pituitary glycopeptide: an important maturation product of pro-opiomelanocortin. Proc Natl Acad Sci U S A 1981; 78:4236-4240
- **42.** Seidah NG, Rochemont J, Hamelin J, Benjannet S, Chretien M. The missing fragment of the pro-sequence of human pro-opiomelanocortin: sequence and evidence for C-terminal amidation. Biochem Biophys Res Commun 1981; 102:710-716
- **43.** Eipper BA, Mains RE. Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. Endocr Rev 1980; 1:1-27
- **44.** Bradbury AF, Smyth DG, Snell CR. Prohormones of beta-melanotropin (beta-melanocytestimulating hormone, beta-MSH) and corticotropin (adrenocorticotropic hormone, ACTH): structure and activation. Ciba Found Symp 1976; 41:61-75
- **45.** Barnea A, Cho G. Acetylation of adrenocorticotropin and beta-endorphin by hypothalamic and pituitary acetyltransferases. Neuroendocrinology 1983; 37:434-439
- **46.** Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213:1394-1397
- **47.** Shibahara S, Morimoto Y, Furutani Y, Notake M, Takahashi H, Shimizu S, Horikawa S, Numa S. Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. Embo J 1983; 2:775-779
- **48.** Sawchenko PE, Swanson LW. Localization, colocalization, and plasticity of corticotropinreleasing factor immunoreactivity in rat brain. Fed Proc 1985; 44:221-227
- **49.** Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropinreleasing-factor receptor. Proc Natl Acad Sci U S A 1993; 90:8967-8971
- 50. Perrin M, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L, Sawchenko P, Vale W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A 1995; 92:2969-2973
- **51.** Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004; 44:525-557
- **52.** DeBold CR, DeCherney GS, Jackson RV, Sheldon WR, Alexander AN, Island DP, Rivier J, Vale W, Orth DN. Effect of synthetic ovine corticotropin-releasing factor: prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol. J Clin Endocrinol Metab 1983; 57:294-298

- **53.** Tse A, Lee AK, Tse FW. Ca2+ signaling and exocytosis in pituitary corticotropes. Cell Calcium 2012; 51:253-259
- **54.** Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 1994; 269:27088-27092
- **55.** Raymond V, Leung PC, Veilleux R, Labrie F. Vasopressin rapidly stimulates phosphatidic acid-phosphatidylinositol turnover in rat anterior pituitary cells. FEBS Lett 1985; 182:196-200
- **56.** Abou-Samra AB, Catt KJ, Aguilera G. Involvement of protein kinase C in the regulation of adrenocorticotropin release from rat anterior pituitary cells. Endocrinology 1986; 118:212-217
- **57.** Plotsky PM. Hypophysiotropic regulation of stress-induced ACTH secretion. Adv Exp Med Biol 1988; 245:65-81
- **58.** Bilezikjian LM, Woodgett JR, Hunter T, Vale WW. Phorbol ester-induced down-regulation of protein kinase C abolishes vasopressin-mediated responses in rat anterior pituitary cells. Molecular endocrinology 1987; 1:555-560
- **59.** Levin N, Blum M, Roberts JL. Modulation of basal and corticotropin-releasing factorstimulated proopiomelanocortin gene expression by vasopressin in rat anterior pituitary. Endocrinology 1989; 125:2957-2966
- **60.** Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52:112-119
- **61.** Lewandowski KC, Lewinski A, Skowronska-Jozwiak E, Stasiak M, Horzelski W, Brabant G. Copeptin under glucagon stimulation. Endocrine 2016; 52:344-351
- **62.** Kacheva S, Kolk K, Morgenthaler NG, Brabant G, Karges W. Gender-specific co-activation of arginine vasopressin and the hypothalamic-pituitary-adrenal axis during stress. Clin Endocrinol (Oxf) 2015; 82:570-576
- **63.** Brownstein MJ, Russell JT, Gainer H. Synthesis, transport, and release of posterior pituitary hormones. Science 1980; 207:373-378
- **64.** Legros JJ, Chiodera P, Demey-Ponsart E. Inhibitory influence of exogenous oxytocin on adrenocorticotropin secretion in normal human subjects. J Clin Endocrinol Metab 1982; 55:1035-1039
- **65.** Legros JJ, Chiodera P, Geenen V, von Frenckell R. Confirmation of the inhibitory influence of exogenous oxytocin on cortisol and ACTH in man: evidence of reproducibility. Acta Endocrinol (Copenh) 1987; 114:345-349
- **66.** Lewis DA, Sherman BM. Oxytocin does not influence adrenocorticotropin secretion in man. J Clin Endocrinol Metab 1985; 60:53-56
- **67.** Antoni FA, Holmes MC, Kiss JZ. Pituitary binding of vasopressin is altered by experimental manipulations of the hypothalamo-pituitary-adrenocortical axis in normal as well as homozygous (di/di) Brattleboro rats. Endocrinology 1985; 117:1293-1299
- **68.** Gibbs DM, Vale W, Rivier J, Yen SS. Oxytocin potentiates the ACTH-releasing activity of CRF(41) but not vasopressin. Life Sci 1984; 34:2245-2249
- **69.** Parker KJ, Buckmaster CL, Schatzberg AF, Lyons DM. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology 2005; 30:924-929
- **70.** Alexander LD, Evans K, Sander LD. A possible involvement of VIP in feeding-induced secretion of ACTH and corticosterone in the rat. Physiol Behav 1995; 58:409-413
- Alexander LD, Sander LD. Involvement of vasopressin and corticotropin-releasing hormone in VIP- and PHI-induced secretion of ACTH and corticosterone. Neuropeptides 1995; 28:167-173

- **72.** Jirikowski GF, Back H, Forssmann WG, Stumpf WE. Coexistence of atrial natriuretic factor (ANF) and oxytocin in neurons of the rat hypothalamus. Neuropeptides 1986; 8:243-249
- **73.** King MS, Baertschi AJ. Physiological concentrations of atrial natriuretic factors with intact N-terminal sequences inhibit corticotropin-releasing factor-stimulated adrenocorticotropin secretion from cultured anterior pituitary cells. Endocrinology 1989; 124:286-292
- **74.** Kellner M, Wiedemann K, Holsboer F. Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and cortisol in man. Life Sci 1992; 50:1835-1842
- **75.** Ur E, Faria M, Tsagarakis S, Anderson JV, Besser GM, Grossman A. Atrial natriuretic peptide in physiological doses does not inhibit the ACTH or cortisol response to corticotrophin-releasing hormone-41 in normal human subjects. J Endocrinol 1991; 131:163-167
- **76.** Taylor T, Dluhy RG, Williams GH. beta-endorphin suppresses adrenocorticotropin and cortisol levels in normal human subjects. J Clin Endocrinol Metab 1983; 57:592-596
- 77. Tsagarakis S, Navarra P, Rees LH, Besser M, Grossman A, Navara P. Morphine directly modulates the release of stimulated corticotrophin-releasing factor-41 from rat hypothalamus in vitro [published erratum appears in Endocrinology 1989 Dec;125(6):3095]. Endocrinology 1989; 124:2330-2335
- **78.** Jackson RV, Grice JE, Hockings GI, Torpy DJ. Naloxone-induced ACTH release: mechanism of action in humans. Clin Endocrinol (Oxf) 1995; 43:423-424
- **79.** Pagotto U, Marsicano G, Fezza F, Theodoropoulou M, Grubler Y, Stalla J, Arzberger T, Milone A, Losa M, Di Marzo V, Lutz B, Stalla GK. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 2001; 86:2687-2696
- **80.** Wade MR, Degroot A, Nomikos GG. Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. Eur J Pharmacol 2006; 551:162-167
- **81.** Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grubler Y, Stalla J, Pasquali R, Lutz B, Stalla GK, Pagotto U. Requirement of Cannabinoid Receptor Type 1 for the Basal Modulation of Hypothalamic-Pituitary-Adrenal Axis Function. Endocrinology 2006;
- 82. Benowitz NL, Jones RT, Lerner CB. Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral delta-9-tetrahydrocannabinol administration in man. J Clin Endocrinol Metab 1976; 42:938-941
- **83.** al-Damluji S. Adrenergic control of the secretion of anterior pituitary hormones. Baillieres Clin Endocrinol Metab 1993; 7:355-392
- **84.** Korbonits M, Kaltsas G, Perry LA, Grossman AB, Monson JP, Besser GM, Trainer PJ. Hexarelin as a test of pituitary reserve in patients with pituitary disease. Clin Endocrinol (Oxf) 1999; 51:369-375
- **85.** Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, Trainer PJ. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 1999; 84:2489-2495
- 86. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001; 86:1169-1174
- **87.** Perras B, Schultes B, Schwaiger R, Metz C, Wesseler W, Born J, Fehm HL. Growth hormone-releasing hormone facilitates hypoglycemia-induced release of cortisol. Regul Pept 2002; 110:85-91
- **88.** Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin,

ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 1997; 18:885-891

- **89.** Kimura T, Shimatsu A, Arimura H, Mori H, Tokitou A, Fukudome M, Nakazaki M, Tei C. Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2. Endocr J 2010; 57:639-644
- **90.** Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJ. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310:996-999
- **91.** Yamamoto D, Ikeshita N, Daito R, Herningtyas EH, Toda K, Takahashi K, Iida K, Takahashi Y, Kaji H, Chihara K, Okimura Y. Neither intravenous nor intracerebroventricular administration of obestatin affects the secretion of GH, PRL, TSH and ACTH in rats. Regul Pept 2007; 138:141-144
- **92.** McKee KK, Tan CP, Palyha OC, Liu J, Feighner SD, Hreniuk DL, Smith RG, Howard AD, Van der Ploeg LH. Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. Genomics 1997; 46:426-434
- **93.** Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach LO, Storjohann L, Stidsen CE, Jones R, Beck-Sickinger AG, Schwartz TW. GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 2007; 148:13-20
- **94.** Luque RM, Cordoba-Chacon J, Ibanez-Costa A, Gesmundo I, Grande C, Gracia-Navarro F, Tena-Sempere M, Ghigo E, Gahete MD, Granata R, Kineman RD, Castano JP. Obestatin plays an opposite role in the regulation of pituitary somatotrope and corticotrope function in female primates and male/female mice. Endocrinology 2014:en20131728
- **95.** Gaillard RC, Favrod-Coune CA, Capponi AM, Muller AF. Corticotropin-releasing activity of the renin-angiotensin system peptides in rat and in man. Neuroendocrinology 1985; 41:511-517
- **96.** Rivier C, Vale W. Effect of angiotensin II on ACTH release in vivo: role of corticotropinreleasing factor. Regul Pept 1983; 7:253-258
- **97.** Murakami K, Ganong WF. Site at which angiotensin II acts to stimulate ACTH secretion in vivo. Neuroendocrinology 1987; 46:231-235
- **98.** Sumitomo T, Suda T, Nakano Y, Tozawa F, Yamada M, Demura H. Angiotensin II increases the corticotropin-releasing factor messenger ribonucleic acid level in the rat hypothalamus. Endocrinology 1991; 128:2248-2252
- **99.** Armando I, Volpi S, Aguilera G, Saavedra JM. Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res 2007; 1142:92-99
- **100.** Armando I, Carranza A, Nishimura Y, Hoe KL, Barontini M, Terron JA, Falcon-Neri A, Ito T, Juorio AV, Saavedra JM. Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation Stress. Endocrinology 2001; 142:3880-3889
- **101.** Strowski MZ, Dashkevicz MP, Parmar RM, Wilkinson H, Kohler M, Schaeffer JM, Blake AD. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology 2002; 75:339-346
- **102.** Lamberts SW, Zuyderwijk J, den Holder F, van Koetsveld P, Hofland L. Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 1989; 50:44-50
- **103.** van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ. Distinct

functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005; 289:E278-287

- 104. Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 2005; 153:R7-R10
- **105.** Stafford PJ, Kopelman PG, Davidson K, McLoughlin L, White A, Rees LH, Besser GM, Coy DH, Grossman A. The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects. Clin Endocrinol (Oxf) 1989; 30:661-666
- 106. Fehm HL, Voigt KH, Lang R, Beinert KE, Raptis S, Pfeiffer EF. Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klin Wochenschr 1976; 54:173-175
- 107. de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, van Aken MO, van der Lelij AJ, de Herder WW, Lamberts SW, Hofland LJ. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009; 94:1118-1124
- 108. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005; 152:645-654
- 109. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010; 362:1846-1848
- **110.** de Herder WW, Lamberts SW. Is there a role for somatostatin and its analogs in Cushing's syndrome? Metabolism 1996; 45:83-85
- **111.** Redei E, Hilderbrand H, Aird F. Corticotropin release inhibiting factor is encoded within prepro-TRH. Endocrinology 1995; 136:1813-1816
- **112.** Redei E, Hilderbrand H, Aird F. Corticotropin release-inhibiting factor is preprothyrotropin-releasing hormone-(178-199). Endocrinology 1995; 136:3557-3563
- **113.** Nicholson WE, Orth DN. Preprothyrotropin-releasing hormone-(178-199) does not inhibit corticotropin release. Endocrinology 1996; 137:2171-2174
- **114.** Gershengorn MC, Arevalo CO, Geras E, Rebecchi MJ. Thyrotropin-releasing hormone stimulation of adrenocorticotropin production by mouse pituitary tumor cells in culture: possible model for anomalous release of adrenocorticotropin by thyrotropin-releasing hormone in some patients with Cushing's disease and Nelson's syndrome. J Clin Invest 1980; 65:1294-1300
- **115.** Bernardini R, Kamilaris TC, Calogero AE, Johnson EO, Gomez MT, Gold PW, Chrousos GP. Interactions between tumor necrosis factor-alpha, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 1990; 126:2876-2881
- **116.** Perlstein RS, Mougey EH, Jackson WE, Neta R. Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormone in vivo. Lymphokine Cytokine Res 1991; 10:141-146
- **117.** Uehara A, Gottschall PE, Dahl RR, Arimura A. Stimulation of ACTH release by human interleukin-1 beta, but not by interleukin-1 alpha, in conscious, freely-moving rats. Biochem Biophys Res Commun 1987; 146:1286-1290
- **118.** Uehara A, Gottschall PE, Dahl RR, Arimura A. Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor. Endocrinology 1987; 121:1580-1582

- **119.** Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996; 17:64-102
- **120.** Veldhuis JD, Iranmanesh A, Johnson ML, Lizarralde G. Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J Clin Endocrinol Metab 1990; 71:452-463
- **121.** Krishnan KR, Ritchie JC, Saunders W, Wilson W, Nemeroff CB, Carroll BJ. Nocturnal and early morning secretion of ACTH and cortisol in humans. Biol Psychiatry 1990; 28:47-57
- **122.** Desir D, Van Cauter E, Beyloos M, Bosson D, Golstein J, Copinschi G. Prolonged pulsatile administration of ovine corticotropin-releasing hormone in normal man. J Clin Endocrinol Metab 1986; 63:1292-1299
- 123. Gambacciani M, Liu JH, Swartz WH, Tueros VS, Rasmussen DD, Yen SS. Intrinsic pulsatility of ACTH release from the human pituitary in vitro. Clin Endocrinol (Oxf) 1987; 26:557-563
- **124.** Kiessling S, Eichele G, Oster H. Adrenal glucocorticoids have a key role in circadian resynchronization in a mouse model of jet lag. J Clin Invest 2010; 120:2600-2609
- **125.** Moore RY, Eichler VB. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res 1972; 42:201-206
- 126. Dunlap JC. Molecular bases for circadian clocks. Cell 1999; 96:271-290
- **127.** Koch CE, Leinweber B, Drengberg BC, Blaum C, Oster H. Interaction between circadian rhythms and stress. Neurobiol Stress 2017; 6:57-67
- **128.** Kornhauser JM, Nelson DE, Mayo KE, Takahashi JS. Photic and circadian regulation of cfos gene expression in the hamster suprachiasmatic nucleus. Neuron 1990; 5:127-134
- **129.** Kornhauser JM, Nelson DE, Mayo KE, Takahashi JS. Regulation of jun-B messenger RNA and AP-1 activity by light and a circadian clock. Science 1992; 255:1581-1584
- **130.** Crosio C, Cermakian N, Allis CD, Sassone-Corsi P. Light induces chromatin modification in cells of the mammalian circadian clock. Nat Neurosci 2000; 3:1241-1247
- **131.** Leliavski A, Shostak A, Husse J, Oster H. Impaired glucocorticoid production and response to stress in Arntl-deficient male mice. Endocrinology 2014; 155:133-142
- **132.** Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, Laposky A, Losee-Olson S, Easton A, Jensen DR, Eckel RH, Takahashi JS, Bass J. Obesity and metabolic syndrome in circadian Clock mutant mice. Science 2005; 308:1043-1045
- **133.** Yang S, Liu A, Weidenhammer A, Cooksey RC, McClain D, Kim MK, Aguilera G, Abel ED, Chung JH. The role of mPer2 clock gene in glucocorticoid and feeding rhythms. Endocrinology 2009; 150:2153-2160
- 134. Barclay JL, Shostak A, Leliavski A, Tsang AH, Johren O, Muller-Fielitz H, Landgraf D, Naujokat N, van der Horst GT, Oster H. High-fat diet-induced hyperinsulinemia and tissuespecific insulin resistance in Cry-deficient mice. Am J Physiol Endocrinol Metab 2013; 304:E1053-1063
- 135. Lamia KA, Papp SJ, Yu RT, Barish GD, Uhlenhaut NH, Jonker JW, Downes M, Evans RM. Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature 2011; 480:552-556
- **136.** Watabe T, Tanaka K, Kumagae M, Itoh S, Hasegawa M, Horiuchi T, Miyabe S, Ohno H, Shimizu N. Diurnal rhythm of plasma immunoreactive corticotropin-releasing factor in normal subjects. Life Sci 1987; 40:1651-1655
- **137.** Cai A, Wise PM. Age-related changes in the diurnal rhythm of CRH gene expression in the paraventricular nuclei. The American journal of physiology 1996; 270:E238-243
- **138.** Cunnah D, Jessop DS, Besser GM, Rees LH. Measurement of circulating corticotrophinreleasing factor in man. J Endocrinol 1987; 113:123-131

- **139.** Ur E, Capstick C, McLoughlin L, Checkley S, Besser GM, Grossman A. Continuous administration of human corticotropin-releasing hormone in the absence of glucocorticoid feedback in man. Neuroendocrinology 1995; 61:191-197
- 140. Yamase K, Takahashi S, Nomura K, Haruta K, Kawashima S. Circadian changes in arginine vasopressin level in the suprachiasmatic nuclei in the rat. Neurosci Lett 1991; 130:255-258
- 141. Jin X, Shearman LP, Weaver DR, Zylka MJ, de Vries GJ, Reppert SM. A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 1999; 96:57-68
- 142. Fahrenkrug J, Hannibal J, Georg B. Diurnal rhythmicity of the canonical clock genes Per1, Per2 and Bmal1 in the rat adrenal gland is unaltered after hypophysectomy. J Neuroendocrinol 2008; 20:323-329
- 143. Ishida A, Mutoh T, Ueyama T, Bando H, Masubuchi S, Nakahara D, Tsujimoto G, Okamura H. Light activates the adrenal gland: timing of gene expression and glucocorticoid release. Cell Metab 2005; 2:297-307
- **144.** Oster H, Damerow S, Hut RA, Eichele G. Transcriptional profiling in the adrenal gland reveals circadian regulation of hormone biosynthesis genes and nucleosome assembly genes. J Biol Rhythms 2006; 21:350-361
- **145.** Yoder JM, Brandeland M, Engeland WC. Phase-dependent resetting of the adrenal clock by ACTH in vitro. Am J Physiol Regul Integr Comp Physiol 2014; 306:R387-393
- **146.** Plotsky PM, Bruhn TO, Vale W. Hypophysiotropic regulation of adrenocorticotropin secretion in response to insulin-induced hypoglycemia. Endocrinology 1985; 117:323-329
- Plotsky PM, Bruhn TO, Vale W. Evidence for multifactor regulation of the adrenocorticotropin secretory response to hemodynamic stimuli. Endocrinology 1985; 116:633-639
- **148.** Berkenbosch F, De Goeij DC, Tilders FJ. Hypoglycemia enhances turnover of corticotropinreleasing factor and of vasopressin in the zona externa of the rat median eminence. Endocrinology 1989; 125:28-34
- **149.** Kim CK, Rivier CL. Nitric oxide and carbon monoxide have a stimulatory role in the hypothalamic-pituitary-adrenal response to physico-emotional stressors in rats. Endocrinology 2000; 141:2244-2253
- **150.** Bernstein HG, Keilhoff G, Seidel B, Stanarius A, Huang PL, Fishman MC, Reiser M, Bogerts B, Wolf G. Expression of hypothalamic peptides in mice lacking neuronal nitric oxide synthase: reduced beta-END immunoreactivity in the arcuate nucleus. Neuroendocrinology 1998; 68:403-411
- 151. Yamada K, Emson P, Hokfelt T. Immunohistochemical mapping of nitric oxide synthase in the rat hypothalamus and colocalization with neuropeptides. J Chem Neuroanat 1996; 10:295-316
- **152.** Keilhoff G, Seidel B, Reiser M, Stanarius A, Huang PL, Bogerts B, Wolf G, Bernstein HG. Lack of neuronal NOS has consequences for the expression of POMC and POMC-derived peptides in the mouse pituitary. Acta Histochem 2001; 103:397-412
- **153.** Jones BJ, Tan T, Bloom SR. Minireview: Glucagon in stress and energy homeostasis. Endocrinology 2012; 153:1049-1054
- **154.** Meeran K, Hattersley A, Mould G, Bloom SR. Venepuncture causes rapid rise in plasma ACTH. Br J Clin Pract 1993; 47:246-247
- **155.** Plumpton FS, Besser GM. The adrenocortical response to surgery and insulin-induced hypoglycaemia in corticosteroid-treated and normal subjects. Br J Surg 1969; 56:216-219
- **156.** Plumpton FS, Besser GM, Cole PV. Corticosteroid treatment and surgery. 1. An investigation of the indications for steroid cover. Anaesthesia 1969; 24:3-11

- **157.** Plumpton FS, Besser GM, Cole PV. Corticosteroid treatment and surgery. 2. The management of steroid cover. Anaesthesia 1969; 24:12-18
- **158.** Khoo B, Boshier PR, Freethy A, Tharakan G, Saeed S, Hill N, Williams EL, Moorthy K, Tolley N, Jiao LR, Spalding D, Palazzo F, Meeran K, Tan T. Redefining the stress cortisol response to surgery. Clin Endocrinol (Oxf) 2017;
- **159.** Ma XM, Levy A, Lightman SL. Rapid changes in heteronuclear RNA for corticotrophinreleasing hormone and arginine vasopressin in response to acute stress. J Endocrinol 1997; 152:81-89
- **160.** Ma XM, Aguilera G. Transcriptional responses of the vasopressin and corticotropinreleasing hormone genes to acute and repeated intraperitoneal hypertonic saline injection in rats. Brain Res Mol Brain Res 1999; 68:129-140
- **161.** Aguilera G, Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitaryadrenal axis: implications for stress adaptation. Regul Pept 2000; 96:23-29
- 162. Itoi K, Mouri T, Takahashi K, Murakami O, Imai Y, Sasaki S, Yoshinaga K, Sasano N. Suppression by glucocorticoid of the immunoreactivity of corticotropin-releasing factor and vasopressin in the paraventricular nucleus of rat hypothalamus. Neurosci Lett 1987; 73:231-236
- **163.** Davis LG, Arentzen R, Reid JM, Manning RW, Wolfson B, Lawrence KL, Baldino F, Jr. Glucocorticoid sensitivity of vasopressin mRNA levels in the paraventricular nucleus of the rat. Proc Natl Acad Sci U S A 1986; 83:1145-1149
- **164.** Abou-Samra AB, Catt KJ, Aguilera G. Biphasic inhibition of adrenocorticotropin release by corticosterone in cultured anterior pituitary cells. Endocrinology 1986; 119:972-977
- **165.** Russell GM, Henley DE, Leendertz J, Douthwaite JA, Wood SA, Stevens A, Woltersdorf WW, Peeters BW, Ruigt GS, White A, Veldhuis JD, Lightman SL. Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J Neurosci 2010; 30:6106-6115
- **166.** Dallman MF, Akana SF, Cascio CS, Darlington DN, Jacobson L, Levin N. Regulation of ACTH secretion: variations on a theme of B. Recent Prog Horm Res 1987; 43:113-173
- **167.** Keller-Wood ME, Dallman MF. Corticosteroid inhibition of ACTH secretion. Endocr Rev 1984; 5:1-24
- **168.** Deng Q, Riquelme D, Trinh L, Low MJ, Tomic M, Stojilkovic S, Aguilera G. Rapid Glucocorticoid Feedback Inhibition of ACTH Secretion Involves Ligand-Dependent Membrane Association of Glucocorticoid Receptors. Endocrinology 2015; 156:3215-3227
- **169.** Taylor AD, Cowell AM, Flower J, Buckingham JC. Lipocortin 1 mediates an early inhibitory action of glucocorticoids on the secretion of ACTH by the rat anterior pituitary gland in vitro. Neuroendocrinology 1993; 58:430-439
- **170.** Evans AN, Liu Y, Macgregor R, Huang V, Aguilera G. Regulation of hypothalamic corticotropin-releasing hormone transcription by elevated glucocorticoids. Molecular endocrinology 2013; 27:1796-1807
- **171.** Drouin J, Bilodeau S, Vallette S. Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency. Clin Genet 2007; 72:175-182
- **172.** Suda T, Tomori N, Yajima F, Ushiyama T, Sumitomo T, Nakagami Y, Demura H, Shizume K. A short negative feedback mechanism regulating corticotropin-releasing hormone release. J Clin Endocrinol Metab 1987; 64:909-913
- 173. Sawchenko PE, Arias C. Evidence for short-loop feedback effects of ACTH on CRF and vasopressin expression in parvocellular neurosecretory neurons. J Neuroendocrinol 1995; 7:721-731
- **174.** Roussel-Gervais A, Couture C, Langlais D, Takayasu S, Balsalobre A, Rueda BR, Zukerberg LR, Figarella-Branger D, Brue T, Drouin J. The Cables1 Gene in Glucocorticoid

Regulation of Pituitary Corticotrope Growth and Cushing Disease. J Clin Endocrinol Metab 2016; 101:513-522

- **175.** Quigley ME, Yen SS. A mid-day surge in cortisol levels. J Clin Endocrinol Metab 1979; 49:945-947
- **176.** Follenius M, Brandenberger G, Hietter B. Diurnal cortisol peaks and their relationships to meals. J Clin Endocrinol Metab 1982; 55:757-761
- **177.** Stimson RH, Mohd-Shukri NA, Bolton JL, Andrew R, Reynolds RM, Walker BR. The postprandial rise in plasma cortisol in men is mediated by macronutrient-specific stimulation of adrenal and extra-adrenal cortisol production. J Clin Endocrinol Metab 2014; 99:160-168
- **178.** Wake DJ, Homer NZ, Andrew R, Walker BR. Acute in vivo regulation of 11betahydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans. J Clin Endocrinol Metab 2006; 91:4682-4688
- **179.** Benedict C, Hallschmid M, Scheibner J, Niemeyer D, Schultes B, Merl V, Fehm HL, Born J, Kern W. Gut protein uptake and mechanisms of meal-induced cortisol release. J Clin Endocrinol Metab 2005; 90:1692-1696
- **180.** Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997; 138:4445-4455
- 181. Ryan AS, Egan JM, Habener JF, Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 1998; 83:2399-2404
- 182. Gil-Lozano M, Perez-Tilve D, Alvarez-Crespo M, Martis A, Fernandez AM, Catalina PA, Gonzalez-Matias LC, Mallo F. GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology 2010; 151:2629-2640
- 183. Lacroix A, Bolte E, Tremblay J, Dupre J, Poitras P, Fournier H, Garon J, Garrel D, Bayard F, Taillefer R, et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing's syndrome. N Engl J Med 1992; 327:974-980
- 184. Gogebakan O, Andres J, Biedasek K, Mai K, Kuhnen P, Krude H, Isken F, Rudovich N, Osterhoff MA, Kintscher U, Nauck M, Pfeiffer AF, Spranger J. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11beta-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012; 61:292-300
- **185.** Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005; 4:141-194
- **186.** Ferrari E, Magri F. Role of neuroendocrine pathways in cognitive decline during aging. Ageing Res Rev 2008; 7:225-233
- **187.** Aguilera G. HPA axis responsiveness to stress: implications for healthy aging. Exp Gerontol 2011; 46:90-95
- **188.** Kasckow JW, Lupien SJ, Behan DP, Welge J, Hauger RJ. Circulating human corticotropinreleasing factor-binding protein levels following cortisol infusions. Life Sci 2001; 69:133-142
- **189.** Tizabi Y, Aguilera G, Gilad GM. Age-related reduction in pituitary corticotropin-releasing hormone receptors in two rat strains. Neurobiol Aging 1992; 13:227-230
- **190.** Lupien S, Lecours AR, Schwartz G, Sharma S, Hauger RL, Meaney MJ, Nair NP. Longitudinal study of basal cortisol levels in healthy elderly subjects: evidence for subgroups. Neurobiol Aging 1996; 17:95-105
- 191. Linkowski P, Van Onderbergen A, Kerkhofs M, Bosson D, Mendlewicz J, Van Cauter E. Twin study of the 24-h cortisol profile: evidence for genetic control of the human circadian clock. The American journal of physiology 1993; 264:E173-181
- **192.** Franz CE, York TP, Eaves LJ, Mendoza SP, Hauger RL, Hellhammer DH, Jacobson KC, Levine S, Lupien SJ, Lyons MJ, Prom-Wormley E, Xian H, Kremen WS. Genetic and

environmental influences on cortisol regulation across days and contexts in middle-aged men. Behav Genet 2010; 40:467-479

- **193.** Cai A, Scarbrough K, Hinkle DA, Wise PM. Fetal grafts containing suprachiasmatic nuclei restore the diurnal rhythm of CRH and POMC mRNA in aging rats. The American journal of physiology 1997; 273:R1764-1770
- **194.** Cooper MS. 11beta-Hydroxysteroid dehydrogenase: a regulator of glucocorticoid response in osteoporosis. J Endocrinol Invest 2008; 31:16-21
- **195.** Holmes MC, Carter RN, Noble J, Chitnis S, Dutia A, Paterson JM, Mullins JJ, Seckl JR, Yau JL. 11beta-hydroxysteroid dehydrogenase type 1 expression is increased in the aged mouse hippocampus and parietal cortex and causes memory impairments. J Neurosci 2010; 30:6916-6920
- 196. Lesniewska B, Miskowiak B, Nowak M, Malendowicz LK. Sex differences in adrenocortical structure and function. XXVII. The effect of ether stress on ACTH and corticosterone in intact, gonadectomized, and testosterone- or estradiol-replaced rats. Res Exp Med (Berl) 1990; 190:95-103
- **197.** Lesniewska B, Nowak M, Malendowicz LK. Sex differences in adrenocortical structure and function. XXVIII. ACTH and corticosterone in intact, gonadectomised and gonadal hormone replaced rats. Horm Metab Res 1990; 22:378-381
- **198.** Jezova D, Kvetnansky R, Vigas M. Sex differences in endocrine response to hyperthermia in sauna. Acta Physiol Scand 1994; 150:293-298
- 199. Jezova D, Jurankova E, Mosnarova A, Kriska M, Skultetyova I. Neuroendocrine response during stress with relation to gender differences. Acta Neurobiol Exp (Wars) 1996; 56:779-785
- 200. Vamvakopoulos NC, Chrousos GP. Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimophism of the stress response and immune/inflammatory reaction. J Clin Invest 1993; 92:1896-1902
- **201.** Kirschbaum C, Wust S, Faig HG, Hellhammer DH. Heritability of cortisol responses to human corticotropin-releasing hormone, ergometry, and psychological stress in humans. J Clin Endocrinol Metab 1992; 75:1526-1530
- **202.** Matthews KA, Gump BB, Owens JF. Chronic stress influences cardiovascular and neuroendocrine responses during acute stress and recovery, especially in men. Health Psychol 2001; 20:403-410
- **203.** Horvath E, Kovacs K. Fine structural cytology of the adenohypophysis in rat and man. J Electron Microsc Tech 1988; 8:401-432
- **204.** Cohen LE, Radovick S. Molecular basis of combined pituitary hormone deficiencies. Endocr Rev 2002; 23:431-442
- **205.** Kapali J, Kabat BE, Schmidt KL, Stallings CE, Tippy M, Jung DO, Edwards BS, Nantie LB, Raeztman LT, Navratil AM, Ellsworth BS. Foxo1 Is Required for Normal Somatotrope Differentiation. Endocrinology 2016; 157:4351-4363
- 206. Zhu X, Zhang J, Tollkuhn J, Ohsawa R, Bresnick EH, Guillemot F, Kageyama R, Rosenfeld MG. Sustained Notch signaling in progenitors is required for sequential emergence of distinct cell lineages during organogenesis. Genes Dev 2006; 20:2739-2753
- **207.** Li CH, Papkoff H. Preparation and properties of growth hormone from human and monkey pituitary glands. Science 1956; 124:1293-1294
- **208.** Li CH, Dixon JS. Human pituitary growth hormone. 32. The primary structure of the hormone: revision. Arch Biochem Biophys 1971; 146:233-236
- **209.** Niall HD, Hogan ML, Sauer R, Rosenblum IY, Greenwood FC. Sequences of pituitary and placental lactogenic and growth hormones: evolution from a primordial peptide by gene reduplication. Proc Natl Acad Sci U S A 1971; 68:866-870

- 210. Owerbach D, Rutter WJ, Martial JA, Baxter JD, Shows TB. Genes for growth hormone, chorionic somatommammotropin, and growth hormones-like gene on chromosome 17 in humans. Science 1980; 209:289-292
- 211. McKusick V, Phillips JI, Bottani A, Antonarakis S, O'Neill M, Kniffin C, Hartz P, Gross M. GROWTH HORMONE 1; GH1. In: McKusick V, ed. Online Mendelian Inheritance in Man. Baltimore, MD, USA: Johns Hopkins University; 2007: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=139250. Accessed 20 Jan 2007
- 212. Frankenne F, Rentier-Delrue F, Scippo ML, Martial J, Hennen G. Expression of the growth hormone variant gene in human placenta. J Clin Endocrinol Metab 1987; 64:635-637
- 213. Liebhaber SA, Urbanek M, Ray J, Tuan RS, Cooke NE. Characterization and histologic localization of human growth hormone-variant gene expression in the placenta. J Clin Invest 1989; 83:1985-1991
- 214. McKusick V, Phillips JI. GROWTH HORMONE 2; GH2. In: McKusick V, ed. Online Mendelian Inheritance in Man. Baltimore, MD: Johns Hopkins University; 2007: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=139240. Accessed 20 Jan 2007
- 215. McKusick V, Phillips JI, Rasooly R. CHORIONIC SOMATOMAMMOTROPIN HORMONE 1; CSH1. In: McKusick V, ed. Online Mendelian Inheritance in Man. Baltimore, MD: Johns Hopkins University; 2007: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=150200. Accessed 20 Jan 2007
- 216. McKusick V, Rasooly R. CHORIONIC SOMATOMAMMOTROPIN HORMONE 2; CSH2. In: McKusick V, ed. Online Mendelian Inheritance in Man. Baltimore, MD: Johns Hopkins University; 2007: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=118820. Accessed 20 Jan 2007
- 217. Rasooly R. CHORIONIC SOMATOMAMMOTROPIN HORMONE-LIKE 1; CSHL1. In: McKusick V, ed. Online Mendelian Inheritance in Man. Baltimore, MD: Johns Hopkins University; 2007: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=603515. Accessed 20 Jan 2007
- 218. Chen EY, Liao YC, Smith DH, Barrera-Saldana HA, Gelinas RE, Seeburg PH. The human growth hormone locus: nucleotide sequence, biology, and evolution. Genomics 1989; 4:479-497
- 219. Bodner M, Castrillo JL, Theill LE, Deerinck T, Ellisman M, Karin M. The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein. Cell 1988; 55:505-518
- 220. Lemaigre FP, Peers B, Lafontaine DA, Mathy-Hartert M, Rousseau GG, Belayew A, Martial JA. Pituitary-specific factor binding to the human prolactin, growth hormone, and placental lactogen genes. DNA 1989; 8:149-159
- 221. Lemaigre FP, Courtois SJ, Durviaux SM, Egan CJ, LaFontaine DA, Rousseau GG. Analysis of cis- and trans-acting elements in the hormone-sensitive human somatotropin gene promoter. J Steroid Biochem 1989; 34:79-83
- 222. Nachtigal MW, Nickel BE, Klassen ME, Zhang WG, Eberhardt NL, Cattini PA. Human chorionic somatomammotropin and growth hormone gene expression in rat pituitary tumour cells is dependent on proximal promoter sequences. Nucleic Acids Res 1989; 17:4327-4337
- 223. Li S, Crenshaw EB, 3rd, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 1990; 347:528-533
- 224. Fox SR, Jong MT, Casanova J, Ye ZS, Stanley F, Samuels HH. The homeodomain protein, Pit-1/GHF-1, is capable of binding to and activating cell-specific elements of both the growth hormone and prolactin gene promoters. Molecular endocrinology 1990; 4:1069-1080

- **225.** Tansey WP, Catanzaro DF. Sp1 and thyroid hormone receptor differentially activate expression of human growth hormone and chorionic somatomammotropin genes. J Biol Chem 1991; 266:9805-9813
- **226.** Nickel BE, Nachtigal MW, Bock ME, Cattini PA. Differential binding of rat pituitary-specific nuclear factors to the 5'-flanking region of pituitary and placental members of the human growth hormone gene family. Mol Cell Biochem 1991; 106:181-187
- **227.** Walker WH, Fitzpatrick SL, Saunders GF. Human placental lactogen transcriptional enhancer. Tissue specificity and binding with specific proteins. J Biol Chem 1990; 265:12940-12948
- **228.** Nachtigal MW, Nickel BE, Cattini PA. Pituitary-specific repression of placental members of the human growth hormone gene family. A possible mechanism for locus regulation. J Biol Chem 1993; 268:8473-8479
- **229.** Jones BK, Monks BR, Liebhaber SA, Cooke NE. The human growth hormone gene is regulated by a multicomponent locus control region. Mol Cell Biol 1995; 15:7010-7021
- **230.** Shewchuk BM, Liebhaber SA, Cooke NE. Specification of unique Pit-1 activity in the hGH locus control region. Proc Natl Acad Sci U S A 2002; 99:11784-11789
- **231.** Elefant F, Cooke NE, Liebhaber SA. Targeted recruitment of histone acetyltransferase activity to a locus control region. J Biol Chem 2000; 275:13827-13834
- **232.** Ho Y, Elefant F, Cooke N, Liebhaber S. A defined locus control region determinant links chromatin domain acetylation with long-range gene activation. Mol Cell 2002; 9:291-302
- **233.** Ho Y, Tadevosyan A, Liebhaber SA, Cooke NE. The juxtaposition of a promoter with a locus control region transcriptional domain activates gene expression. EMBO Rep 2008; 9:891-898
- **234.** Gil-Puig C, Seoane S, Blanco M, Macia M, Garcia-Caballero T, Segura C, Perez-Fernandez R. Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation. Eur J Endocrinol 2005; 153:335-344
- **235.** Frohman LA, Burek L, Stachura MA. Characterization of growth hormone of different molecular weights in rat, dog and human pituitaries. Endocrinology 1972; 91:262-269
- **236.** Baumann G, Winter RJ, Shaw M. Circulating molecular variants of growth hormone in childhood. Pediatr Res 1987; 22:21-22
- 237. Baumann G, Stolar MW, Amburn K. Molecular forms of circulating growth hormone during spontaneous secretory episodes and in the basal state. J Clin Endocrinol Metab 1985; 60:1216-1220
- **238.** Herington AC, Ymer S, Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J Clin Invest 1986; 77:1817-1823
- **239.** Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ, Barnard R, Waters MJ, Wood WI. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330:537-543
- 240. Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ. Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 2000; 141:4342-4348
- **241.** Baumann G, Shaw MA. Plasma transport of the 20,000-dalton variant of human growth hormone (20K): evidence for a 20K-specific binding site. J Clin Endocrinol Metab 1990; 71:1339-1343
- 242. Ross RJ, Esposito N, Shen XY, Von Laue S, Chew SL, Dobson PR, Postel-Vinay MC, Finidori J. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Molecular endocrinology 1997; 11:265-273

- **243.** Gossard F, Dihl F, Pelletier G, Dubois PM, Morel G. In situ hybridization to rat brain and pituitary gland of growth hormone cDNA. Neurosci Lett 1987; 79:251-256
- **244.** Aberg ND, Brywe KG, Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. TheScientificWorldJournal 2006; 6:53-80
- 245. Thorner MO, Perryman RL, Cronin MJ, Rogol AD, Draznin M, Johanson A, Vale W, Horvath E, Kovacs K. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest 1982; 70:965-977
- **246.** Mayo K, Vale W, Rivier J, Rosenfeld M, Evans R. Expression-cloning and sequence of a cDNA encoding human growth hormone-releasing factor. Nature 1983; 306:86-88
- 247. Gubler U, Monahan J, Lomedico P, Bhatt R, Collier K, Hoffman B, Bohlen P, Esch F, Ling N, Zeytin F, Brazeau P, Poonian M, Gage L. Cloning and sequence analysis of cDNA for the precursor of human growth hormone-releasing factor, somatocrinin. Proc Natl Acad Sci U S A 1983; 80:4311-4314
- **248.** Mayo K. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molecular endocrinology 1992; 6:1734-1744
- **249.** Barinaga M, Yamonoto G, Rivier C, Vale W, Evans R, Rosenfeld M. Transcriptional regulation of growth hormone gene expression by growth hormone-releasing factor. Nature 1983; 306:84-85
- **250.** Fukata J, Diamond D, Martin J. Effects of rat growth hormone (rGH)-releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitary cells. Endocrinology 1985; 117:457-467
- **251.** Campbell R, Scanes C. Evolution of the growth hormone-releasing factor (GRF) family of peptides. Growth Regul 1992; 2:175-191
- **252.** Shen L, Pictet R, Rutter W. Human somatostatin I: sequence of the cDNA. Proc Natl Acad Sci U S A 1982; 79:4575-4579
- **253.** Siler T, VandenBerg G, Yen S, Brazeau P, Vale W, Guillemin R. Inhibition of growth hormone release in humans by somatostatin. J Clin Endocrinol Metab 1973; 37:632-634
- **254.** Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179:77-79
- **255.** Tannenbaum GS, Epelbaum J, Bowers CY. Interrelationship between the Novel Peptide Ghrelin and Somatostatin/Growth Hormone-Releasing Hormone in Regulation of Pulsatile Growth Hormone Secretion. Endocrinology 2003; 144:967-974
- 256. Broglio F, Koetsveld Pv P, Benso A, Gottero C, Prodam F, Papotti M, Muccioli G, Gauna C, Hofland L, Deghenghi R, Arvat E, Van Der Lely AJ, Ghigo E. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab 2002; 87:4829-4832
- **257.** Norrelund H, Hansen TK, Orskov H, Hosoda H, Kojima M, Kangawa K, Weeke J, Moller N, Christiansen JS, Jorgensen JO. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol (Oxf) 2002; 57:539-546
- **258.** Shimada M, Date Y, Mondal MS, Toshinai K, Shimbara T, Fukunaga K, Murakami N, Miyazato M, Kangawa K, Yoshimatsu H, Matsuo H, Nakazato M. Somatostatin suppresses ghrelin secretion from the rat stomach. Biochem Biophys Res Commun 2003; 302:520-525
- **259.** Vale W, Rivier C, Brazeau P, Guillemin R. Effects of somatostatin on the secretion of thyrotropin and prolactin. Endocrinology 1974; 95:968-977
- **260.** Siler TM, Yen SC, Vale W, Guillemin R. Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor. J Clin Endocrinol Metab 1974; 38:742-745

- **261.** Liddle R. Physiology of somatostatin and its analogues. UpToDate version 14.3. Wellesley, MA, United States of America: UpToDate, Inc.; 2006.
- **262.** Patel Y, Greenwood M, Panetta R, Hukovic N, Grigorakis S, Robertson L, Srikant C. Molecular biology of somatostatin receptor subtypes. Metabolism 1996; 45:31-38
- **263.** Peineau S, Guimiot F, Csaba Z, Jacquier S, Fafouri A, Schwendimann L, de Roux N, Schulz S, Gressens P, Auvin S, Dournaud P. Somatostatin receptors type 2 and 5 expression and localization during human pituitary development. Endocrinology 2014; 155:33-39
- **264.** Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995; 16:427-442
- **265.** Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growthhormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660
- **266.** Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Van der Ploeg LH, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273:974-977
- **267.** Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002; 87:2988
- **268.** Chan CB, Cheng CH. Identification and functional characterization of two alternatively spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream Acanthopagrus schlegeli. Mol Cell Endocrinol 2004; 214:81-95
- **269.** Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000; 279:909-913
- **270.** Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008; 132:387-396
- **271.** Lim CT, Kola B, Grossman A, Korbonits M. The expression of ghrelin O-acyltransferase (GOAT) in human tissues. Endocr J 2011; 58:707-710
- **272.** Momany FA, Bowers CY, Reynolds GA, Chang D, Hong A, Newlander K. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology 1981; 108:31-39
- 273. Beaumont NJ, Skinner VO, Tan TM, Ramesh BS, Byrne DJ, MacColl GS, Keen JN, Bouloux PM, Mikhailidis DP, Bruckdorfer KR, Vanderpump MP, Srai KS. Ghrelin Can Bind to a Species of High Density Lipoprotein Associated with Paraoxonase. J Biol Chem 2003; 278:8877-8880
- **274.** De Vriese C, Gregoire F, Lema-Kisoka R, Waelbroeck M, Robberecht P, Delporte C. Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. Endocrinology 2004; 145:4997-5005
- **275.** Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, Grossman AB. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86:881-887
- 276. Caminos JE, Nogueiras R, Blanco M, Seoane LM, Bravo S, Alvarez CV, Garcia-Caballero T, Casanueva FF, Dieguez C. Cellular distribution and regulation of ghrelin messenger ribonucleic acid in the rat pituitary gland. Endocrinology 2003; 144:5089-5097
- **277.** Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growthhormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660

- **278.** Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 2002; 440:235-254
- 279. Wren A, Small C, Abbott C, Dhillo W, Seal L, Cohen M, Batterham R, Taheri S, Stanley S, Ghatei M, Bloom S. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50:2540-2547
- **280.** Wren A, Seal L, Cohen M, Brynes A, Frost G, Murphy K, Dhillo W, Ghatei M, Bloom S. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992
- **281.** Date Y, Nakazato M, Hashiguchi S, Dezaki K, Mondal M, Hosoda H, Kojima M, Kangawa K, Arima T, Matsuo H, Yada T, Matsukura S. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002; 51:124-129
- **282.** Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000; 85:4908-4911
- **283.** Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003; 23:7973-7981
- **284.** Hassouna R, Zizzari P, Tomasetto C, Veldhuis JD, Fiquet O, Labarthe A, Cognet J, Steyn F, Chen C, Epelbaum J, Tolle V. An early reduction in GH peak amplitude in preproghrelindeficient male mice has a minor impact on linear growth. Endocrinology 2014; 155:3561-3571
- **285.** Wortley KE, Anderson KD, Garcia K, Murray JD, Malinova L, Liu R, Moncrieffe M, Thabet K, Cox HJ, Yancopoulos GD, Wiegand SJ, Sleeman MW. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A 2004; 101:8227-8232
- **286.** Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A 2004; 101:4679-4684
- **287.** Xie TY, Ngo ST, Veldhuis JD, Jeffery PL, Chopin LK, Tschop M, Waters MJ, Tolle V, Epelbaum J, Chen C, Steyn FJ. Effect of Deletion of Ghrelin-O-Acyltransferase on the Pulsatile Release of Growth Hormone in Mice. J Neuroendocrinol 2015; 27:872-886
- 288. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159:1029-1037
- 289. Cassoni P, Ghe C, Marrocco T, Tarabra E, Allia E, Catapano F, Deghenghi R, Ghigo E, Papotti M, Muccioli G. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol 2004; 150:173-184
- **290.** Muccioli G, Pons N, Ghe C, Catapano F, Granata R, Ghigo E. Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 2004; 498:27-35
- **291.** Tsubota Y, Owada-Makabe K, Yukawa K, Maeda M. Hypotensive effect of des-acyl ghrelin at nucleus tractus solitarii of rat. Neuroreport 2005; 16:163-166
- 292. Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga M. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005; 54:18-24

- **293.** Neary NM, Druce MR, Small CJ, Bloom SR. Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect. Gut 2006; 55:135
- **294.** Chen CY, Inui A, Asakawa A, Fujino K, Kato I, Chen CC, Ueno N, Fujimiya M. Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology 2005; 129:8-25
- **295.** Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995; 80:942-947
- **296.** Seoane LM, Tovar S, Baldelli R, Arvat E, Ghigo E, Casanueva FF, Dieguez C. Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats. Eur J Endocrinol 2000; 143:R7-9
- **297.** Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormonereleasing hexapeptide, GHRP. Endocrinology 1991; 128:2027-2035
- **298.** Casanueva FF, Burguera B, Muruais C, Dieguez C. Acute administration of corticoids: a new and peculiar stimulus of growth hormone secretion in man. J Clin Endocrinol Metab 1990; 70:234-237
- **299.** Burguera B, Muruais C, Penalva A, Dieguez C, Casanueva FF. Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man. Neuroendocrinology 1990; 51:51-58
- **300.** Strickland AL, Underwood LE, Voina SJ, French FS, Van Wyk JJ. Growth retardation in Cushing's syndrome. Am J Dis Child 1972; 123:207-213
- **301.** Giustina A, Wehrenberg WB. The role of glucocorticoids in the regulation of Growth Hormone secretion: mechanisms and clinical significance. Trends Endocrinol Metab 1992; 3:306-311
- **302.** Veldhuis JD, Roemmich JN, Richmond EJ, Bowers CY. Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition. Endocr Rev 2006; 27:101-140
- **303.** Kok P, Paulo RC, Cosma M, Mielke KL, Miles JM, Bowers CY, Veldhuis JD. Estrogen supplementation selectively enhances hypothalamo-pituitary sensitivity to ghrelin in postmenopausal women. J Clin Endocrinol Metab 2008; 93:4020-4026
- 304. Amit Tanna RM, Harinderjeet Sandhu, Jake Powrie, Stephen Thomas, Anna Brackenridge, Louise Breen & Paul Carroll. Oral and transdermal oestrogen treatments have differing effects on GH sensitivity in hypopituitary women receiving GH replacement. Endocrine Abstract 2010; 21 P286
- 305. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991; 72:374-381
- **306.** Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA. Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. Eur J Endocrinol 2014; 166:207-213
- **307.** Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425-432
- 308. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269:540-543

- **309.** Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404:661-671
- **310.** Jin L, Burguera BG, Couce ME, Scheithauer BW, Lamsan J, Eberhardt NL, Kulig E, Lloyd RV. Leptin and leptin receptor expression in normal and neoplastic human pituitary: evidence of a regulatory role for leptin on pituitary cell proliferation. J Clin Endocrinol Metab 1999; 84:2903-2911
- 311. Korbonits M, Chitnis MM, Gueorguiev M, Norman D, Rosenfelder N, Suliman M, Jones TH, Noonan K, Fabbri A, Besser GM, Burrin JM, Grossman AB. The release of leptin and its effect on hormone release from human pituitary adenomas. Clin Endocrinol (Oxf) 2001; 54:781-789
- **312.** Kristiansen MT, Clausen LR, Nielsen S, Blaabjerg O, Ledet T, Rasmussen LM, Jorgensen JO. Expression of leptin receptor isoforms and effects of leptin on the proliferation and hormonal secretion in human pituitary adenomas. Horm Res 2004; 62:129-136
- **313.** Saleri R, Giustina A, Tamanini C, Valle D, Burattin A, Wehrenberg WB, Baratta M. Leptin stimulates growth hormone secretion via a direct pituitary effect combined with a decreased somatostatin tone in a median eminence-pituitary perifusion study. Neuroendocrinology 2004; 79:221-228
- **314.** Tannenbaum GS, Lapointe M, Gurd W, Finkelstein JA. Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats: roles of growth hormone-releasing factor and somatostatin. Endocrinology 1990; 127:3087-3095
- **315.** Ozata M, Dieguez C, Casanueva FF. The inhibition of growth hormone secretion presented in obesity is not mediated by the high leptin levels: a study in human leptin deficiency patients. J Clin Endocrinol Metab 2003; 88:312-316
- **316.** Gutierrez-Pascual E, Martinez-Fuentes AJ, Pinilla L, Tena-Sempere M, Malagon MM, Castano JP. Direct pituitary effects of kisspeptin: activation of gonadotrophs and somatotrophs and stimulation of luteinising hormone and growth hormone secretion. J Neuroendocrinol 2007; 19:521-530
- **317.** Kadokawa H, Suzuki S, Hashizume T. Kisspeptin-10 stimulates the secretion of growth hormone and prolactin directly from cultured bovine anterior pituitary cells. Anim Reprod Sci 2008; 105:404-408
- **318.** Whitlock BK, Daniel JA, Wilborn RR, Maxwell HS, Steele BP, Sartin JL. Interaction of kisspeptin and the somatotropic axis. Neuroendocrinology 2010; 92:178-188
- 319. Jayasena CN, Comninos AN, Narayanaswamy S, Bhalla S, Abbara A, Ganiyu-Dada Z, Busbridge M, Ghatei MA, Bloom SR, Dhillo WS. Acute and chronic effects of kisspeptin-54 administration on GH, prolactin and TSH secretion in healthy women. Clin Endocrinol (Oxf) 2014; 81:891-898
- **320.** Massara F, Camanni F. Effect of various adrenergic receptor stimulating and blocking agents on human growth hormone secretion. J Endocrinol 1972; 54:195-206
- **321.** Chihara K, Minamitani N, Kaji H, Kodama H, Kita T, Fujita T. Noradrenergic modulation of human pancreatic growth hormone-releasing factor (hpGHRF1-44)-induced growth hormone release in conscious male rabbits: involvement of endogenous somatostatin. Endocrinology 1984; 114:1402-1406
- **322.** Milner RD, Burns EC. Investigation of suspected growth hormone deficiency. On behalf of the Health Services Human Growth Hormone Committee. Arch Dis Child 1982; 57:944-947
- **323.** Grossman A, Weerasuriya K, Al-Damluji S, Turner P, Besser GM. Alpha 2-adrenoceptor agonists stimulate growth hormone secretion but have no acute effects on plasma cortisol under basal conditions. Horm Res 1987; 25:65-71
- **324.** Masala A, Delitala G, Alagna S, Devilla L. Effect of pimozide on levodopa-induced growth hormone release in man. Clin Endocrinol (Oxf) 1977; 7:253-256

- **325.** Cammani F, Massara F. Phentolamine inhibition of human growth hormone secretion induced by L-DOPA. Horm Metab Res 1972; 4:128
- **326.** Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19:717-797
- **327.** Friend K, Iranmanesh A, Login IS, Veldhuis JD. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release. Eur J Endocrinol 1997; 137:377-386
- **328.** Taylor BJ, Smith PJ, Brook CG. Inhibition of physiological growth hormone secretion by atropine. Clin Endocrinol (Oxf) 1985; 22:497-501
- **329.** Massara F, Ghigo E, Demislis K, Tangolo D, Mazza E, Locatelli V, Muller EE, Molinatti GM, Camanni F. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects. Neuroendocrinology 1986; 43:670-675
- **330.** Wehrenberg WB, Wiviott SD, Voltz DM, Giustina A. Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement. Endocrinology 1992; 130:1445-1450
- **331.** Vance ML, Kaiser DL, Frohman LA, Rivier J, Vale WW, Thorner MO. Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man. J Clin Endocrinol Metab 1987; 64:1136-1141
- **332.** Grossman A. Brain opiates and neuroendocrine function. Clin Endocrinol Metab 1983; 12:725-746
- 333. Moretti C, Fabbri A, Gnessi L, Cappa M, Calzolari A, Fraioli F, Grossman A, Besser GM. Naloxone inhibits exercise-induced release of PRL and GH in athletes. Clin Endocrinol (Oxf) 1983; 18:135-138
- **334.** Miki N, Ono M, Shizume K. Evidence that opiatergic and alpha-adrenergic mechanisms stimulate rat growth hormone release via growth hormone-releasing factor (GRF). Endocrinology 1984; 114:1950-1952
- **335.** Olsen J, Peroski M, Kiczek M, Grignol G, Merchenthaler I, Dudas B. Intimate associations between the endogenous opiate systems and the growth hormone-releasing hormone system in the human hypothalamus. Neuroscience 2014; 258:238-245
- **336.** Dudas B, Merchenthaler I. Topography and associations of leu-enkephalin and luteinizing hormone-releasing hormone neuronal systems in the human diencephalon. J Clin Endocrinol Metab 2003; 88:1842-1848
- **337.** Delitala G, Tomasi PA, Palermo M, Ross RJ, Grossman A, Besser GM. Opioids stimulate growth hormone (GH) release in man independently of GH-releasing hormone. J Clin Endocrinol Metab 1989; 69:356-358
- **338.** Wenger T, Toth BE, Martin BR. Effects of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. Life Sci 1995; 56:2057-2063
- **339.** Rettori V, Wenger T, Snyder G, Dalterio S, McCann SM. Hypothalamic action of delta-9tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. Neuroendocrinology 1988; 47:498-503
- **340.** Rettori V, Aguila MC, Gimeno MF, Franchi AM, McCann SM. In vitro effect of delta 9tetrahydrocannabinol to stimulate somatostatin release and block that of luteinizing hormone-releasing hormone by suppression of the release of prostaglandin E2. Proc Natl Acad Sci U S A 1990; 87:10063-10066
- **341.** Zbucki RL, Sawicki B, Hryniewicz A, Winnicka MM. Cannabinoids enhance gastric X/A-like cells activity. Folia Histochem Cytobiol 2008; 46:219-224
- **342.** Senin LL, Al-Massadi O, Folgueira C, Castelao C, Pardo M, Barja-Fernandez S, Roca-Rivada A, Amil M, Crujeiras AB, Garcia-Caballero T, Gabellieri E, Leis R, Dieguez C,

Pagotto U, Casanueva FF, Seoane LM. The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake. PloS one 2013; 8:e80339

- 343. Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, Amin F, Harvey-White J, Liposits Z, Kunos G, Grossman AB, Fekete C, Korbonits M. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PloS one 2008; 3:e1797
- 344. Kola B, Wittman G, Bodnar I, Amin F, Lim CT, Olah M, Christ-Crain M, Lolli F, van Thuijl H, Leontiou CA, Fuzesi T, Dalino P, Isidori AM, Harvey-White J, Kunos G, Nagy GM, Grossman AB, Fekete C, Korbonits M. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. FASEB J 2013; 27:5112-5121
- **345.** Lim CT, Kola B, Korbonits M. The ghrelin/GOAT/GHS-R system and energy metabolism. Rev Endocr Metab Disord 2011; 12:173-186
- **346.** Lim CT, Kola B, Feltrin D, Perez-Tilve D, Tschop MH, Grossman AB, Korbonits M. Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. Mol Cell Endocrinol 2013; 365:303-308
- **347.** Giustina A, Licini M, Schettino M, Doga M, Pizzocolo G, Negro-Vilar A. Physiological role of galanin in the regulation of anterior pituitary function in humans. The American journal of physiology 1994; 266:E57-61
- **348.** Cantalamessa L, Catania A, Reschini E, Peracchi M. Inhibitory effect of calcitonin on growth hormone and insulin secretion in man. Metabolism 1978; 27:987-992
- **349.** Petralito A, Lunetta M, Liuzzo A, Mangiafico RA, Fiore CE. Effects of salmon calcitonin on insulin-induced growth hormone release in man. Horm Metab Res 1979; 11:641-643
- **350.** Harfstrand A, Eneroth P, Agnati L, Fuxe K. Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: relationship to hypothalamic catecholamines. Regul Pept 1987; 17:167-179
- **351.** Rettori V, Milenkovic L, Aguila MC, McCann SM. Physiologically significant effect of neuropeptide Y to suppress growth hormone release by stimulating somatostatin discharge. Endocrinology 1990; 126:2296-2301
- **352.** Catzeflis C, Pierroz DD, Rohner-Jeanrenaud F, Rivier JE, Sizonenko PC, Aubert ML. Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats. Endocrinology 1993; 132:224-234
- **353.** Adams EF, Venetikou MS, Woods CA, Lacoumenta S, Burrin JM. Neuropeptide Y directly inhibits growth hormone secretion by human pituitary somatotropic tumours. Acta Endocrinol (Copenh) 1987; 115:149-154
- **354.** Korbonits M, Little JA, Forsling ML, Tringali G, Costa A, Navarra P, Trainer PJ, Grossman AB. The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants. J Neuroendocrinol 1999; 11:521-528
- **355.** Watanobe H, Tamura T. Stimulation by neuropeptide Y of growth hormone secretion in prolactinoma in vivo. Neuropeptides 1996; 30:429-432
- **356.** Antonijevic IA, Murck H, Bohlhalter S, Frieboes RM, Holsboer F, Steiger A. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 2000; 39:1474-1481
- **357.** Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164:567-574
- **358.** Goth MI, Lyons CE, Canny BJ, Thorner MO. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992; 130:939-944

- **359.** Jarry H, Leonhardt S, Schmidt WE, Creutzfeldt W, Wuttke W. Contrasting effects of pituitary adenylate cyclase activating polypeptide (PACAP) on in vivo and in vitro prolactin and growth hormone release in male rats. Life Sci 1992; 51:823-830
- **360.** Propato-Mussafiri R, Kanse SM, Ghatei MA, Bloom SR. Pituitary adenylate cyclaseactivating polypeptide releases 7B2, adrenocorticotrophin, growth hormone and prolactin from the mouse and rat clonal pituitary cell lines AtT-20 and GH3. J Endocrinol 1992; 132:107-113
- **361.** Chiodera P, Volpi R, Capretti L, Caffarri G, Magotti MG, Coiro V. Effects of intravenously infused pituitary adenylate cyclase-activating polypeptide on adenohypophyseal Hormone secretion in normal men. Neuroendocrinology 1996; 64:242-246
- **362.** Shahmoon S, Rubinfeld H, Wolf I, Cohen ZR, Hadani M, Shimon I, Rubinek T. The aging suppressor klotho: a potential regulator of growth hormone secretion. Am J Physiol Endocrinol Metab 2014; 307:E326-334
- **363.** Peterfreund RA, Vale WW. Somatostatin analogs inhibit somatostatin secretion from cultured hypothalamus cells. Neuroendocrinology 1984; 39:397-402
- **364.** Aguila MC, McCann SM. The influence of hGRF, CRF, TRH and LHRH on SRIF release from median eminence fragments. Brain Res 1985; 348:180-182
- **365.** Sheppard MC, Kronheim S, Pimstone BL. Stimulation by growth hormone of somatostatin release from the rat hypothalamus in vitro. Clin Endocrinol (Oxf) 1978; 9:583-586
- **366.** Ross RJ, Tsagarakis S, Grossman A, Nhagafoong L, Touzel RJ, Rees LH, Besser GM. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH. Clin Endocrinol (Oxf) 1987; 27:727-733
- **367.** Aguila MC, McCann SM. Growth hormone increases somatostatin release and messenger ribonucleic acid levels in the rat hypothalamus. Brain Res 1993; 623:89-94
- **368.** Qi X, Reed J, Englander EW, Chandrashekar V, Bartke A, Greeley GH, Jr. Evidence that growth hormone exerts a feedback effect on stomach ghrelin production and secretion. Exp Biol Med (Maywood) 2003; 228:1028-1032
- **369.** Goldenberg N, Barkan A. Factors regulating growth hormone secretion in humans. Endocrinol Metab Clin North Am 2007; 36:37-55
- **370.** Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 1981; 212:1279-1281
- **371.** Yamashita S, Melmed S. Insulin-like growth factor I action on rat anterior pituitary cells: suppression of growth hormone secretion and messenger ribonucleic acid levels. Endocrinology 1986; 118:176-182
- **372.** Eden S, Bolle P, Modigh K. Monoaminergic control of episodic growth hormone secretion in the rat: effects of reserpine, alpha-methyl-p-tyrosine, p-chlorophenylalanine, and haloperidol. Endocrinology 1979; 105:523-529
- **373.** Iranmanesh A, Grisso B, Veldhuis JD. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab 1994; 78:526-535
- **374.** Toogood AA, Nass RM, Pezzoli SS, O'Neill PA, Thorner MO, Shalet SM. Preservation of growth hormone pulsatility despite pituitary pathology, surgery, and irradiation. J Clin Endocrinol Metab 1997; 82:2215-2221
- **375.** Surya S, Symons K, Rothman E, Barkan AL. Complex rhythmicity of growth hormone secretion in humans. Pituitary 2006; 9:121-125
- **376.** Tannenbaum GS, Painson JC, Lengyel AM, Brazeau P. Paradoxical enhancement of pituitary growth hormone (GH) responsiveness to GH-releasing factor in the face of high somatostatin tone. Endocrinology 1989; 124:1380-1388

- **377.** Plotsky PM, Vale W. Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat. Science 1985; 230:461-463
- **378.** Cataldi M, Magnan E, Guillaume V, Dutour A, Conte-Devolx B, Lombardi G, Oliver C. Relationship between hypophyseal portal GHRH and somatostatin and peripheral GH levels in the conscious sheep. J Endocrinol Invest 1994; 17:717-722
- **379.** Vance ML, Kaiser DL, Martha PM, Jr., Furlanetto R, Rivier J, Vale W, Thorner MO. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy. J Clin Endocrinol Metab 1989; 68:22-28
- **380.** Roelfsema F, Biermasz NR, Veldman RG, Veldhuis JD, Frolich M, Stokvis-Brantsma WH, Wit JM. Growth hormone (GH) secretion in patients with an inactivating defect of the GH-releasing hormone (GHRH) receptor is pulsatile: evidence for a role for non-GHRH inputs into the generation of GH pulses. J Clin Endocrinol Metab 2001; 86:2459-2464
- 381. van den Berg G, Veldhuis JD, Frolich M, Roelfsema F. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 1996; 81:2460-2467
- **382.** Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 1994; 78:1312-1319
- 383. Cordoba-Chacon J, Gahete MD, Castano JP, Kineman RD, Luque RM. Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice. Am J Physiol Endocrinol Metab 2011; 300:E46-54
- **384.** Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 1997; 94:7239-7244
- **385.** Zadik Z, Chalew SA, McCarter RJ, Jr., Meistas M, Kowarski AA. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 1985; 60:513-516
- **386.** Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323:1-6
- **387.** Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. Science 2010; 328:321-326
- **388.** Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol 2013; 9:366-376
- **389.** Nass R, Farhy LS, Liu J, Pezzoli SS, Johnson ML, Gaylinn BD, Thorner MO. Agedependent decline in acyl-ghrelin concentrations and reduced association of acyl-ghrelin and growth hormone in healthy older adults. J Clin Endocrinol Metab 2014; 99:602-608
- **390.** Nass R. Growth hormone axis and aging. Endocrinol Metab Clin North Am 2013; 42:187-199
- **391.** Van Cauter E, Kerkhofs M, Caufriez A, Van Onderbergen A, Thorner MO, Copinschi G. A quantitative estimation of growth hormone secretion in normal man: reproducibility and relation to sleep and time of day. J Clin Endocrinol Metab 1992; 74:1441-1450
- **392.** Holl RW, Hartman ML, Veldhuis JD, Taylor WM, Thorner MO. Thirty-second sampling of plasma growth hormone in man: correlation with sleep stages. J Clin Endocrinol Metab 1991; 72:854-861

- **393.** Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. Jama 2000; 284:861-868
- **394.** Van Cauter E, Latta F, Nedeltcheva A, Spiegel K, Leproult R, Vandenbril C, Weiss R, Mockel J, Legros JJ, Copinschi G. Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res 2004; 14 Suppl A:S10-17
- **395.** Golstein J, Van Cauter E, Desir D, Noel P, Spire JP, Refetoff S, Copinschi G. Effects of "jet lag" on hormonal patterns. IV. Time shifts increase growth hormone release. J Clin Endocrinol Metab 1983; 56:433-440
- **396.** Jaffe CA, Friberg RD, Barkan AL. Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses. J Clin Invest 1993; 92:695-701
- **397.** Jaffe CA, Turgeon DK, Friberg RD, Watkins PB, Barkan AL. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study. J Clin Endocrinol Metab 1995; 80:3321-3326
- **398.** Yildiz BO, Suchard MA, Wong M-L, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. PNAS 2004; 101:10434-10439
- **399.** Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls. Neuroendocrinology 1992; 56:566-573
- Weikel JC, Wichniak A, Ising M, Brunner H, Friess E, Held K, Mathias S, Schmid DA, Uhr M, Steiger A. Ghrelin promotes slow-wave sleep in humans. Am J Physiol Endocrinol Metab 2003; 284:E407-415
- **401.** Sutton J, Lazarus L. Growth hormone in exercise: comparison of physiological and pharmacological stimuli. J Appl Physiol 1976; 41:523-527
- **402.** Lassarre C, Girard F, Durand J, Raynaud J. Kinetics of human growth hormone during submaximal exercise. J Appl Physiol 1974; 37:826-830
- **403.** Raynaud J, Capderou A, Martineaud JP, Bordachar J, Durand J. Intersubject variability in growth hormone time course during different types of work. J Appl Physiol 1983; 55:1682-1687
- **404.** Felsing NE, Brasel JA, Cooper DM. Effect of low and high intensity exercise on circulating growth hormone in men. J Clin Endocrinol Metab 1992; 75:157-162
- **405.** Vanhelder WP, Goode RC, Radomski MW. Effect of anaerobic and aerobic exercise of equal duration and work expenditure on plasma growth hormone levels. Eur J Appl Physiol Occup Physiol 1984; 52:255-257
- 406. Schmidt A, Maier C, Schaller G, Nowotny P, Bayerle-Eder M, Buranyi B, Luger A, Wolzt M. Acute exercise has no effect on ghrelin plasma concentrations. Horm Metab Res 2004; 36:174-177
- **407.** Roth J, Glick SM, Yalow RS, Berson SA. Hypoglycemia: a potent stimulus to secretion of growth hormone. Science 1963; 140:987-988
- **408.** Greenwood FC, Landon J, Stamp TC. The plasma sugar, free fatty acid, cortisol, and growth hormone response to insulin. I. In control subjects. J Clin Invest 1966; 45:429-436
- **409.** Hindmarsh PC, Smith PJ, Taylor BJ, Pringle PJ, Brook CG. Comparison between a physiological and a pharmacological stimulus of growth hormone secretion: response to stage IV sleep and insulin-induced hypoglycaemia. Lancet 1985; 2:1033-1035
- **410.** Tatar P, Vigas M. Role of alpha 1- and alpha 2-adrenergic receptors in the growth hormone and prolactin response to insulin-induced hypoglycemia in man. Neuroendocrinology 1984; 39:275-280

- **411.** Jaffe CA, DeMott-Friberg R, Barkan AL. Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli. J Clin Invest 1996; 97:934-940
- **412.** Broglio F, Prodam F, Gottero C, Destefanis S, Me E, Riganti F, Giordano R, Picu A, Balbo M, Van der Lely AJ, Ghigo E, Arvat E. Ghrelin does not mediate the somatotroph and corticotroph responses to the stimulatory effect of glucagon or insulin-induced hypoglycaemia in humans. Clin Endocrinol (Oxf) 2004; 60:699-704
- **413.** Carey LC, Cloutier CT, Lowery BD. Growth hormone and adrenal cortical response to shock and trauma in the human. Ann Surg 1971; 174:451-460
- **414.** Vigas M, Malatinsky J, Nemeth S, Jurcovicova J. Alpha-adrenergic control of growth hormone release during surgical stress in man. Metabolism 1977; 26:399-402
- **415.** Roth A, Cligg SM, Yalow RS, Berson SA. Secretion of growth hormone: physiological and experimental modification. Metabolism 1963; 12:557-559
- **416.** Penalva A, Burguera B, Casabiell X, Tresguerres JA, Dieguez C, Casanueva FF. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin? Neuroendocrinology 1989; 49:551-554
- **417.** Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87:240-244
- **418.** Broglio F, Benso A, Gottero C, Prodam F, Grottoli S, Tassone F, Maccario M, Casanueva FF, Dieguez C, Deghenghi R, Ghigo E, Arvat E. Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans. Clin Endocrinol (Oxf) 2002; 57:265-271
- **419.** Hayford JT, Danney MM, Hendrix JA, Thompson RG. Integrated concentration of growth hormone in juvenile-onset diabetes. Diabetes 1980; 29:391-398
- **420.** Asplin CM, Faria AC, Carlsen EC, Vaccaro VA, Barr RE, Iranmanesh A, Lee MM, Veldhuis JD, Evans WS. Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 69:239-245
- **421.** Salgado LR, Semer M, Nery M, Knoepfelmacher M, Lerario AC, Povoa G, Jana S, Villares SM, Wajchenberg BL, Liberman B, Nicolau W. Effect of glycemic control on growth hormone and IGFBP-1 secretion in patients with type I diabetes mellitus. J Endocrinol Invest 1996; 19:433-440
- **422.** Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG, Thorner MO. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 1988; 81:968-975
- **423.** Soliman AT, Hassan AE, Aref MK, Hintz RL, Rosenfeld RG, Rogol AD. Serum insulin-like growth factors I and II concentrations and growth hormone and insulin responses to arginine infusion in children with protein-energy malnutrition before and after nutritional rehabilitation. Pediatr Res 1986; 20:1122-1130
- **424.** Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991; 72:51-59
- **425.** Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. The American journal of physiology 1997; 272:E1108-1116
- **426.** Ghigo E, Mazza E, Corrias A, Imperiale E, Goffi S, Arvat E, Bellone J, De Sanctis C, Muller EE, Camanni F. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children. Metabolism 1989; 38:631-633

- **427.** Loche S, Pintor C, Cappa M, Ghigo E, Puggioni R, Locatelli V, Muller EE. Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children. Acta Endocrinol (Copenh) 1989; 120:624-628
- **428.** Cordido F, Casanueva FF, Dieguez C. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. J Clin Endocrinol Metab 1989; 68:290-293
- **429.** Cordido F, Penalva A, Peino R, Casanueva FF, Dieguez C. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects. Metabolism 1995; 44:745-748
- **430.** Maccario M, Aimaretti G, Grottoli S, Gauna C, Tassone F, Corneli G, Rossetto R, Wu Z, Strasburger CJ, Ghigo E. Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency. Int J Obes Relat Metab Disord 2001; 25:1233-1239
- **431.** Grottoli S, Gauna C, Tassone F, Aimaretti G, Corneli G, Wu Z, Strasburger CJ, Dieguez C, Casanueva FF, Ghigo E, Maccario M. Both fasting-induced leptin reduction and GH increase are blunted in Cushing's syndrome and in simple obesity. Clin Endocrinol (Oxf) 2003; 58:220-228
- **432.** Pedersen MH, Svart MV, Lebeck J, Bidlingmaier M, Stodkilde-Jorgensen H, Pedersen SB, Moller N, Jessen N, Jorgensen JOL. Substrate Metabolism and Insulin Sensitivity During Fasting in Obese Human Subjects: Impact of GH Blockade. J Clin Endocrinol Metab 2017; 102:1340-1349
- **433.** Carro E, Senaris R, Considine RV, Casanueva FF, Dieguez C. Regulation of in vivo growth hormone secretion by leptin. Endocrinology 1997; 138:2203-2206
- **434.** Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50:707-709
- **435.** Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, Jorgensen JO. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 2002; 56:203-206
- **436.** Leidy HJ, Gardner JK, Frye BR, Snook ML, Schuchert MK, Richard EL, Williams NI. Circulating Ghrelin Is Sensitive to Changes in Body Weight during a Diet and Exercise Program in Normal-Weight Young Women. J Clin Endocrinol Metab 2004; 89:2659-2664
- **437.** Lindeman JH, Pijl H, Van Dielen FM, Lentjes EG, Van Leuven C, Kooistra T. Ghrelin and the hyposomatotropism of obesity. Obes Res 2002; 10:1161-1166
- **438.** Tamboli RA, Antoun J, Sidani RM, Clements A, Harmata EE, Marks-Shulman P, Gaylinn BD, Williams B, Clements RH, Albaugh VL, Abumrad NN. Metabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans. Diabetes Obes Metab 2017; 19:1267-1275
- **439.** Sukkar MY, Hunter WM, Passmore R. Changes in plasma levels of insulin and growthhormone levels after a protein meal. Lancet 1967; 2:1020-1022
- **440.** Parker ML, Hammond JM, Daughaday WH. The arginine provocative test: an aid in the diagnosis of hyposomatotropism. J Clin Endocrinol Metab 1967; 27:1129-1136
- **441.** Alba-Roth J, Muller OA, Schopohl J, von Werder K. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab 1988; 67:1186-1189





Figure 1: POMC and its derivatives



Figure 2: Diagram showing the release of ACTH from corticotroph cells. CRH binds to to a particular receptor that leads to activation of cAMP. The rise in cAMP inhibits TREK-1, thus leading to the depolarisation of the cell and subsequently influx of calcium via VGCC. The rise in intracellular calcium leads to the exocytosis and release of ACTH.



Figure 3: Schematic diagram showing the synthesis of ghrelin and obestatin from the same precursor, preproghrelin. Preproghrelin is an 117 amino acid precursor encoded at chromosome 3. Cleavage of this protein leads to the production of ghrelin, a 28 amino acid peptide, and obestatin, a 23 amino acid protein. Ghrelin can be present as both des-acyl- and acyl-ghrelin (figure modified from (291)).



Figure 4: Typical response to hypoglycaemia (≤2.2 mmol/l) induced by 0.15 U/kg Actrapid i.v. in a normal subject. Peak cortisol is ≥550 nmol/l.



Figure 5: Regulation of ACTH. Green arrows denote stimulatory influences, red arrows denote inhibitory influences.



Figure 6: Hypophysiotrophic hormones influencing GH release.



Figure 7: Regulation of GH. Green arrows denote stimulatory influences, red arrows denote inhibitory influences.





Figure 8: Pulsatility of circulating GH levels in adult men and women.

Figure 9: Normal response of GH to insulin-induced hypoglycaemia ($\leq 2.2 \text{ mmol/l}$). Peak GH secreted is $\geq 6.66 \mu \text{g/L}$.



Figure 10: GH response to 75g oral glucose in 8 non-acromegalic, non-diabetic women, given at time 0. Error bars denote SD. Note the high variability of the baseline GH level due to the pulsatile nature of GH secretion. GH levels fall to <0.4 μ g/L at 120 minutes.